| Experimental Factor Ontology (EFO) Information | |
| Identifier | EFO_0007355 |
| Description | A primary or metastatic malignant neoplasm involving the male reproductive system. Representative examples include prostate carcinoma, penile carcinoma, testicular seminoma, and testicular embryonal carcinoma. [NCIT: C8561] | Trait category |
Cancer
|
| Synonyms |
27 synonyms
|
| Mapped terms |
12 mapped terms
|
| Child trait(s) | 4 child traits |
| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS000030 (PrCa) |
PGP000019 | Schumacher FR et al. Nat Genet (2018) |
Prostate cancer | prostate carcinoma | 147 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000030/ScoringFiles/PGS000030.txt.gz |
| PGS000044 (PrCa66) |
PGP000031 | Pashayan N et al. Br J Cancer (2015) |
Prostate cancer | prostate carcinoma | 66 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000044/ScoringFiles/PGS000044.txt.gz |
| PGS000049 (PRS103_PrCa) |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |
Prostate cancer | prostate carcinoma | 103 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000049/ScoringFiles/PGS000049.txt.gz |
| PGS000067 (PCa_PHS) |
PGP000047 | Seibert TM et al. BMJ (2018) |
Prostate cancer | prostate carcinoma | 54 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000067/ScoringFiles/PGS000067.txt.gz |
| PGS000084 (CC_Prostate) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Prostate cancer | prostate carcinoma | 161 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000084/ScoringFiles/PGS000084.txt.gz |
| PGS000086 (CC_Testis) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Testicular cancer | testicular carcinoma, Testicular Germ Cell Tumor |
52 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000086/ScoringFiles/PGS000086.txt.gz |
| PGS000160 (cGRS_Prostate) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Prostate cancer | prostate carcinoma | 79 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000160/ScoringFiles/PGS000160.txt.gz |
| PGS000333 (PRS_PC) |
PGP000100 | Mars N et al. Nat Med (2020) |
Prostate cancer | prostate carcinoma | 6,606,785 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000333/ScoringFiles/PGS000333.txt.gz | |
| PGS000348 (PRS_PrCa) |
PGP000113 | Black MH et al. Prostate (2020) |
Prostate cancer | prostate carcinoma | 72 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000348/ScoringFiles/PGS000348.txt.gz |
| PGS000565 (PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 21 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000565/ScoringFiles/PGS000565.txt.gz | |
| PGS000566 (PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,111,494 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000566/ScoringFiles/PGS000566.txt.gz | |
| PGS000567 (PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 78 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000567/ScoringFiles/PGS000567.txt.gz | |
| PGS000568 (PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,401 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000568/ScoringFiles/PGS000568.txt.gz | |
| PGS000569 (PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000569/ScoringFiles/PGS000569.txt.gz | |
| PGS000570 (PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,111,493 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000570/ScoringFiles/PGS000570.txt.gz | |
| PGS000571 (PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 100 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000571/ScoringFiles/PGS000571.txt.gz | |
| PGS000572 (PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,809 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000572/ScoringFiles/PGS000572.txt.gz | |
| PGS000573 (PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 31 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000573/ScoringFiles/PGS000573.txt.gz | |
| PGS000574 (PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,111,493 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000574/ScoringFiles/PGS000574.txt.gz | |
| PGS000575 (PRSWEB_PHECODE185_C61_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 47 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000575/ScoringFiles/PGS000575.txt.gz | |
| PGS000576 (PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 905 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000576/ScoringFiles/PGS000576.txt.gz | |
| PGS000577 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 117 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000577/ScoringFiles/PGS000577.txt.gz | |
| PGS000578 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 117 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000578/ScoringFiles/PGS000578.txt.gz | |
| PGS000579 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 122 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000579/ScoringFiles/PGS000579.txt.gz | |
| PGS000580 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 118 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000580/ScoringFiles/PGS000580.txt.gz | |
| PGS000581 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 377 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000581/ScoringFiles/PGS000581.txt.gz | |
| PGS000582 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 377 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000582/ScoringFiles/PGS000582.txt.gz | |
| PGS000583 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,119,311 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000583/ScoringFiles/PGS000583.txt.gz | |
| PGS000584 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,120,596 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000584/ScoringFiles/PGS000584.txt.gz | |
| PGS000585 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,301 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000585/ScoringFiles/PGS000585.txt.gz | |
| PGS000586 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,023 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000586/ScoringFiles/PGS000586.txt.gz | |
| PGS000587 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 26,418 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000587/ScoringFiles/PGS000587.txt.gz | |
| PGS000588 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 178,259 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000588/ScoringFiles/PGS000588.txt.gz | |
| PGS000589 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 42 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000589/ScoringFiles/PGS000589.txt.gz | |
| PGS000590 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,119,236 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000590/ScoringFiles/PGS000590.txt.gz | |
| PGS000591 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 80 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000591/ScoringFiles/PGS000591.txt.gz | |
| PGS000592 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Prostate cancer | prostate carcinoma | 1,334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000592/ScoringFiles/PGS000592.txt.gz | |
| PGS000593 (PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Cancer of other male genital organs | male reproductive organ cancer | 45 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000593/ScoringFiles/PGS000593.txt.gz | |
| PGS000594 (PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Cancer of other male genital organs | male reproductive organ cancer | 97 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000594/ScoringFiles/PGS000594.txt.gz | |
| PGS000595 (PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 9 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000595/ScoringFiles/PGS000595.txt.gz | |
| PGS000596 (PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 5 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000596/ScoringFiles/PGS000596.txt.gz | |
| PGS000597 (PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 771 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000597/ScoringFiles/PGS000597.txt.gz | |
| PGS000598 (PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 6 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000598/ScoringFiles/PGS000598.txt.gz | |
| PGS000599 (PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 31 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000599/ScoringFiles/PGS000599.txt.gz | |
| PGS000600 (PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 250 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000600/ScoringFiles/PGS000600.txt.gz | |
| PGS000601 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 40 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000601/ScoringFiles/PGS000601.txt.gz | |
| PGS000602 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 40 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000602/ScoringFiles/PGS000602.txt.gz | |
| PGS000603 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000603/ScoringFiles/PGS000603.txt.gz | |
| PGS000604 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Malignant neoplasm of testis | testicular carcinoma | 44 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000604/ScoringFiles/PGS000604.txt.gz | |
| PGS000662 (GRS.PCa.269) |
PGP000122 | Conti DV et al. Nat Genet (2021) |
Prostate cancer | prostate carcinoma | 269 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000662/ScoringFiles/PGS000662.txt.gz |
| PGS000714 (PRS55_PC) |
PGP000130 | Sipeky C et al. Sci Rep (2020) |
Prostate cancer | prostate carcinoma | 55 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000714/ScoringFiles/PGS000714.txt.gz |
| PGS000719 (PRS_Prostate) |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Prostate cancer | prostate carcinoma | 134 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000719/ScoringFiles/PGS000719.txt.gz |
| PGS000733 (PHS46+African) |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Prostate cancer | prostate carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000733/ScoringFiles/PGS000733.txt.gz | |
| PGS000741 (PCa_PHS2) |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Prostate cancer | prostate carcinoma | 46 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000741/ScoringFiles/PGS000741.txt.gz |
| PGS000742 (PHS166) |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Prostate cancer | prostate carcinoma | 166 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000742/ScoringFiles/PGS000742.txt.gz | |
| PGS000751 (PRS_PrCa_EuropeanWeighted) |
PGP000156 | Du Z et al. Int J Cancer (2019) |
Prostate cancer | prostate carcinoma | 178 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000751/ScoringFiles/PGS000751.txt.gz |
| PGS000795 (CC_Prostate_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Prostate cancer | prostate carcinoma | 161 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000795/ScoringFiles/PGS000795.txt.gz |
| PGS000796 (CC_Testis_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Testicular cancer | testicular carcinoma, Testicular Germ Cell Tumor |
52 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000796/ScoringFiles/PGS000796.txt.gz |
| PGS000878 (PRS4_PC) |
PGP000224 | Oh JJ et al. Front Oncol (2020) |
Prostate cancer | prostate carcinoma | 4 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000878/ScoringFiles/PGS000878.txt.gz |
| PGS000881 (GRS72_PCa) |
PGP000227 | Xu J et al. Prostate (2021) |
Prostate cancer | prostate carcinoma | 72 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000881/ScoringFiles/PGS000881.txt.gz |
| PGS001111 (GBE_cancer1038) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Male genital tract cancer | male reproductive organ cancer | 313 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001111/ScoringFiles/PGS001111.txt.gz |
| PGS001164 (GBE_cancer1045) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Testicular cancer | testicular carcinoma | 280 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001164/ScoringFiles/PGS001164.txt.gz |
| PGS001291 (GBE_cancer1044) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Prostate cancer | prostate carcinoma | 948 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001291/ScoringFiles/PGS001291.txt.gz |
| PGS001805 (portability-PLR_185) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Prostate cancer | prostate carcinoma | 2,579 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001805/ScoringFiles/PGS001805.txt.gz |
| PGS002016 (portability-ldpred2_185) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Prostate cancer | prostate carcinoma | 450,963 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002016/ScoringFiles/PGS002016.txt.gz |
| PGS002240 (prscs_prostatecancer) |
PGP000271 | Mars N et al. Cell Genom (2022) |
Prostate cancer | prostate carcinoma | 1,092,093 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002240/ScoringFiles/PGS002240.txt.gz | |
| PGS002241 (ldpred_prostatecancer) |
PGP000271 | Mars N et al. Cell Genom (2022) |
Prostate cancer | prostate carcinoma | 6,497,734 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002241/ScoringFiles/PGS002241.txt.gz | |
| PGS002268 (PRS_csPCa) |
PGP000298 | Song SH et al. Investig Clin Urol (2022) |
Prostate cancer | prostate carcinoma | 29 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002268/ScoringFiles/PGS002268.txt.gz |
| PGS002791 (PRS126_Pca) |
PGP000371 | Ruan X et al. Prostate (2022) |
Prostate cancer | prostate carcinoma | 126 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002791/ScoringFiles/PGS002791.txt.gz | |
| PGS002792 (PRS67_Pca) |
PGP000371 | Ruan X et al. Prostate (2022) |
Prostate cancer | prostate carcinoma | 67 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002792/ScoringFiles/PGS002792.txt.gz | |
| PGS002793 (PRS84_Pca) |
PGP000371 | Ruan X et al. Prostate (2022) |
Prostate cancer | prostate carcinoma | 82 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002793/ScoringFiles/PGS002793.txt.gz | |
| PGS002796 (GRS232_Eur) |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Prostate cancer | prostate carcinoma | 232 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002796/ScoringFiles/PGS002796.txt.gz |
| PGS002797 (GRS67_His) |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Prostate cancer | prostate carcinoma | 67 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002797/ScoringFiles/PGS002797.txt.gz |
| PGS002798 (GRS128_Afr) |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Prostate cancer | prostate carcinoma | 128 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002798/ScoringFiles/PGS002798.txt.gz |
| PGS002799 (GRS138_EA) |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Prostate cancer | prostate carcinoma | 138 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002799/ScoringFiles/PGS002799.txt.gz |
| PGS003331 (PHS290) |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Prostate cancer | prostate carcinoma | 290 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003331/ScoringFiles/PGS003331.txt.gz | |
| PGS003383 (best_PRAD) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Prostate adenocarcinoma | prostate adenocarcinoma | 168,700 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003383/ScoringFiles/PGS003383.txt.gz |
| PGS003415 (PGS268_PCa) |
PGP000428 | Nyberg T et al. J Clin Oncol (2022) |
Prostate cancer | prostate carcinoma | 268 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003415/ScoringFiles/PGS003415.txt.gz | |
| PGS003418 (PRState_Eur) |
PGP000430 | Pagadala MS et al. BMC Cancer (2022) |
Prostate cancer | prostate cancer | 7 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003418/ScoringFiles/PGS003418.txt.gz |
| PGS003419 (PRState_Trans) |
PGP000430 | Pagadala MS et al. BMC Cancer (2022) |
Prostate cancer | prostate cancer | 14 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003419/ScoringFiles/PGS003419.txt.gz |
| PGS003460 (PRS278_PCa) |
PGP000453 | Chen F et al. Eur Urol (2023) |
Prostate cancer | prostate carcinoma | 278 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003460/ScoringFiles/PGS003460.txt.gz |
| PGS003743 (PRS118_PrC) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Prostate cancer | prostate carcinoma | 118 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003743/ScoringFiles/PGS003743.txt.gz | |
| PGS003765 (GRS.PCa.451) |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Prostate cancer | prostate carcinoma | 451 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003765/ScoringFiles/PGS003765.txt.gz |
| PGS003766 (GRS.PCa.451.TOPMed) |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Prostate cancer | prostate carcinoma | 451 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003766/ScoringFiles/PGS003766.txt.gz |
| PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,139,671 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003985/ScoringFiles/PGS003985.txt.gz | |
| PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 26,873 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004001/ScoringFiles/PGS004001.txt.gz | |
| PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,045,276 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004027/ScoringFiles/PGS004027.txt.gz | |
| PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,045,276 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004042/ScoringFiles/PGS004042.txt.gz | |
| PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 777,255 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004055/ScoringFiles/PGS004055.txt.gz | |
| PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 777,255 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004071/ScoringFiles/PGS004071.txt.gz | |
| PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,105,199 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004085/ScoringFiles/PGS004085.txt.gz | |
| PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,105,199 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004099/ScoringFiles/PGS004099.txt.gz | |
| PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 200 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004109/ScoringFiles/PGS004109.txt.gz | |
| PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 765 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004125/ScoringFiles/PGS004125.txt.gz | |
| PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 945,385 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004139/ScoringFiles/PGS004139.txt.gz | |
| PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Prostate cancer | prostate carcinoma | 1,139,693 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004155/ScoringFiles/PGS004155.txt.gz | |
| PGS004251 (PRS125_prostate) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Prostate cancer | prostate carcinoma | 125 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004251/ScoringFiles/PGS004251.txt.gz |
| PGS004581 (PRCA_PRSCS) |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Prostate cancer | prostate carcinoma | 1,102,292 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004581/ScoringFiles/PGS004581.txt.gz |
| PGS004599 (PRS102_Pca) |
PGP000577 | Ruan X et al. J Clin Med (2023) |
Prostate cancer | prostate carcinoma | 102 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004599/ScoringFiles/PGS004599.txt.gz |
| PGS004601 (PRS17_Pca) |
PGP000579 | Wu Y et al. Clin Genet (2023) |
Prostate cancer | prostate carcinoma | 17 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004601/ScoringFiles/PGS004601.txt.gz |
| PGS004694 (prostate_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Prostate cancer | prostate carcinoma | 1,016,708 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004694/ScoringFiles/PGS004694.txt.gz | |
| PGS004815 (prostate_cancer_PRSmix_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Prostate cancer | prostate carcinoma | 922,102 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004815/ScoringFiles/PGS004815.txt.gz |
| PGS004816 (prostate_cancer_PRSmixPlus_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Prostate cancer | prostate carcinoma | 922,104 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004816/ScoringFiles/PGS004816.txt.gz |
| PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Prostate cancer | prostate carcinoma | 765,876 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004872/ScoringFiles/PGS004872.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM000061 | PGS000030 (PrCa) |
PSS000041| European Ancestry| 74,849 individuals |
PGP000019 | Schumacher FR et al. Nat Genet (2018) |
Reported Trait: Prostate cancer | OR: 1.86 [1.83, 1.89] | — | — | Top 7 Genetic PCs, country | Samples were also part of the variant association |
| PPM001971 | PGS000030 (PrCa) |
PSS000983| European Ancestry| 81,094 individuals |
PGP000173 | Darst BF et al. Eur Urol (2021) |Ext. |
Reported Trait: Prostate cancer in carriers of rare pathogenic, likely pathogenic and/or deleterious germline variants | OR: 2.58 [2.45, 2.71] | — | — | Age, PCs (1-10) | Only 145 SNPs from PGS000030 were utilised. 2 SNPs were not included as they were not present in the UK Biobank (UKB) data and had an imputation info score of > 0.50 (median info score = 0.997). |
| PPM005133 | PGS000030 (PrCa) |
PSS003583| European Ancestry| 450 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prostate cancer in BRCA1 carriers | OR: 1.73 [1.28, 2.33] | AUROC: 0.62 [0.54, 0.69] | — | PCs(1-3) | — |
| PPM005134 | PGS000030 (PrCa) |
PSS003583| European Ancestry| 450 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prostate cancer in BRCA1 carriers | OR: 1.74 [1.29, 2.35] | — | — | PCs(1-3), family history of prostate cancer in first and second degree relatives | — |
| PPM005135 | PGS000030 (PrCa) |
PSS003584| European Ancestry| 1,074 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prostate cancer in BRCA2 carriers | OR: 1.6 [1.34, 1.91] | AUROC: 0.62 [0.57, 0.67] | — | PCs(1-3) | — |
| PPM005136 | PGS000030 (PrCa) |
PSS003584| European Ancestry| 1,074 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prostate cancer in BRCA2 carriers | OR: 1.59 [1.32, 1.9] | — | — | PCs(1-3), family history of prostate cancer in first and second degree relatives | — |
| PPM012886 | PGS000030 (PrCa) |
PSS009594| Ancestry Not Reported| 4,580 individuals |
PGP000292 | Saad M et al. Lancet Oncol (2022) |Ext. |
Reported Trait: Prostate cancer | OR: 1.835 [1.664, 2.023] | AUROC: 0.672 [0.645, 0.698] | — | — | — |
| PPM013015 | PGS000030 (PrCa) |
PSS009648| European Ancestry| 991 individuals |
PGP000322 | Klein RJ et al. NPJ Precis Oncol (2022) |Ext. |
Reported Trait: Prostate cancer metastasis or death | HR: 1.25 [1.1, 1.41] | — | — | — | — |
| PPM013016 | PGS000030 (PrCa) |
PSS009649| European Ancestry| 1,000 individuals |
PGP000322 | Klein RJ et al. NPJ Precis Oncol (2022) |Ext. |
Reported Trait: Prostate cancer metastasis or death | HR: 1.65 | — | — | — | — |
| PPM013017 | PGS000030 (PrCa) |
PSS009648| European Ancestry| 991 individuals |
PGP000322 | Klein RJ et al. NPJ Precis Oncol (2022) |Ext. |
Reported Trait: Incident prostate cancer | HR: 1.25 [1.11, 1.41] | — | — | — | — |
| PPM013018 | PGS000030 (PrCa) |
PSS009649| European Ancestry| 1,000 individuals |
PGP000322 | Klein RJ et al. NPJ Precis Oncol (2022) |Ext. |
Reported Trait: Incident prostate cancer | HR: 1.69 | — | — | — | — |
| PPM013019 | PGS000030 (PrCa) |
PSS009650| European Ancestry| 1,991 individuals |
PGP000322 | Klein RJ et al. NPJ Precis Oncol (2022) |Ext. |
Reported Trait: Prostate cancer metastasis or death | — | AUROC: 0.63 | — | — | — |
| PPM015484 | PGS000030 (PrCa) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (tumor stage T4) | OR: 1.14 [0.93, 1.4] | AUROC: 0.51 [0.438, 0.578] | — | — | — |
| PPM015481 | PGS000030 (PrCa) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Prostate cancer | OR: 1.23 [0.91, 1.67] | AUROC: 0.538 [0.516, 0.56] | — | — | — |
| PPM015486 | PGS000030 (PrCa) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (Gleason score >=8) | OR: 1.13 [1.02, 1.25] | AUROC: 0.511 [0.475, 0.547] | — | — | — |
| PPM015519 | PGS000030 (PrCa) |
PSS009971| Multi-ancestry (including European)| 36,422 individuals |
PGP000381 | Hao L et al. Nat Med (2022) |Ext. |
Reported Trait: Prostate cancer | OR: 2.22 [1.98, 2.48] | — | — | 4 genetic PCs | — |
| PPM000105 | PGS000044 (PrCa66) |
PSS000069| European Ancestry| 4,967 individuals |
PGP000032 | Pashayan N et al. Genet Med (2015) |Ext. |
Reported Trait: aggressive prostate cancer (Gleason score ⩾7) | — | — | OR (above vs. below 50th percentile of PRS): 1.56 [1.15, 2.1] | — | — |
| PPM000104 | PGS000044 (PrCa66) |
PSS000068| European Ancestry| 17,012 individuals |
PGP000031 | Pashayan N et al. Br J Cancer (2015) |
Reported Trait: Elevated serum prostate-specific antigen (PSA) levels | — | — | OR (per 1-point increase in PRS): 1.23 [1.1, 1.37] | cancer stage, Gleason score | — |
| PPM000123 | PGS000049 (PRS103_PrCa) |
PSS000075| European Ancestry| 1,525 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |
Reported Trait: Prostate cancer in male carriers of BRCA1/2 mutations | OR: 1.56 [1.35, 1.81] | AUROC: 0.62 [0.58, 0.66] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
| PPM000124 | PGS000049 (PRS103_PrCa) |
PSS000077| European Ancestry| 1,366 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |
Reported Trait: Low prostate cancer aggressiveness (Gleason score < 7) | OR: 1.44 [1.1, 1.87] | — | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
| PPM000125 | PGS000049 (PRS103_PrCa) |
PSS000076| European Ancestry| 3,325 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |
Reported Trait: High prostate cancer aggressiveness (Gleason score ≥ 7) | OR: 1.67 [1.37, 2.04] | — | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
| PPM000182 | PGS000067 (PCa_PHS) |
PSS000105| European Ancestry| 5,456 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: aggressive prostate cancer | — | — | HR (Hazard ratio; top 2% vs. average risk): 2.9 [2.4, 3.4] | — | — |
| PPM000184 | PGS000067 (PCa_PHS) |
PSS000106| European Ancestry| 6,411 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: any prostate cancer | — | — | HR (Hazard ratio; top 2% vs. average risk): 2.5 [2.2, 2.8] | — | — |
| PPM001675 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 2% vs. middle 40%): 2.1 [1.99, 2.21] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM001677 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR bottom 20% vs. middle 40%): 0.65 [0.63, 0.67] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000393 | PGS000067 (PCa_PHS) |
PSS000221| African Ancestry| 4,437 individuals |
PGP000058 | Huynh-Le MP et al. Nat Commun (2021) |Ext. |
Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 2.4 [2.3, 2.6] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000392 | PGS000067 (PCa_PHS) |
PSS000222| Additional Asian Ancestries| 1,901 individuals |
PGP000058 | Huynh-Le MP et al. Nat Commun (2021) |Ext. |
Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.2 [4.8, 5.6] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000391 | PGS000067 (PCa_PHS) |
PSS000223| European Ancestry| 50,656 individuals |
PGP000058 | Huynh-Le MP et al. Nat Commun (2021) |Ext. |
Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.6 [5.2, 6.0] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000390 | PGS000067 (PCa_PHS) |
PSS000220| Multi-ancestry (including European)| 56,994 individuals |
PGP000058 | Huynh-Le MP et al. Nat Commun (2021) |Ext. |
Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.9 [5.5, 6.3] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM001679 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (HR top 20% vs. bottom 20%): 2.21 [2.04, 2.38] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000394 | PGS000067 (PCa_PHS) |
PSS000224| Multi-ancestry (including European)| 34,558 individuals |
PGP000058 | Huynh-Le MP et al. Nat Commun (2021) |Ext. |
Reported Trait: Age of prostate cancer death | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.7 [4.6, 7.0] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM001683 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (bottom 20% vs. middle 40%): 0.7 [0.68, 0.73] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM001681 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (top 2% vs. middle 40%): 1.91 [1.79, 2.04] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM000186 | PGS000067 (PCa_PHS) |
PSS000107| European Ancestry| 5,048 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: very aggressive prostate cancer | — | — | HR (Hazard ratio; top 2% vs. average risk): 3.0 [2.2, 4.0] | — | — |
| PPM001673 | PGS000067 (PCa_PHS) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |Ext. |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 20% vs. bottom 20%): 2.47 [2.32, 2.62] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
| PPM001812 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 5.15 [3.29, 6.18] | — | Only 46 out of the 54 variants were used from Seibert et al's polygenic risk score (PGS000067) |
| PPM001813 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.44 [0.4, 0.49] | — | Only 46 out of the 54 variants were used from Seibert et al's polygenic risk score (PGS000067) |
| PPM001817 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 3.72 [2.89, 4.43] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001818 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 6.12 [4.18, 7.67] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001819 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.41 [0.35, 0.47] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001823 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 3.2 [2.59, 3.78] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001824 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 4.96 [3.61, 6.14] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001825 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.45 [0.39, 0.5] | — | Only 46 out of the 54 variants were utilised from Seibert et al's polygenic risk score (PGS000067) |
| PPM001811 | PGS000067 (PCa_PHS) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 3.29 [2.73, 3.77] | — | Only 46 out of the 54 variants were used from Seibert et al's polygenic risk score (PGS000067) |
| PPM000187 | PGS000067 (PCa_PHS) |
PSS000107| European Ancestry| 5,048 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: very aggressive prostate cancer (age at onset) | — | — | z-test (p-value) <: 1.00e-16 | — | — |
| PPM000183 | PGS000067 (PCa_PHS) |
PSS000105| European Ancestry| 5,456 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: aggressive prostate cancer (age at onset) | — | — | z-test (p-value) <: 1.00e-16 | — | — |
| PPM000185 | PGS000067 (PCa_PHS) |
PSS000106| European Ancestry| 6,411 individuals |
PGP000047 | Seibert TM et al. BMJ (2018) |
Reported Trait: any prostate cancer (age at onset) | — | — | z-test (p-value) <: 1.00e-16 | — | — |
| PPM000204 | PGS000084 (CC_Prostate) |
PSS000123| European Ancestry| 201,516 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Prostate cancer | OR: 1.44 [1.41, 1.47] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. | Results from meta-analysis of GERA and UKB. Sample overlap: the GERA dataset contributed to the effect estimates for 4 of the 161 variants in the prostate cancer PRS. |
| PPM002050 | PGS000084 (CC_Prostate) |
PSS001023| European Ancestry| 184,225 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident prostate cancer | HR: 1.39 [1.35, 1.43] | AUROC: 0.74 C-index: 0.738 (0.004) |
— | Age at assessment, family history of prostate cancer, genotyping array, PCs(1-15), family history of prostate cancer | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM017163 | PGS000084 (CC_Prostate) |
PSS010151| European Ancestry| 4,476 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Prostate cancer | HR: 1.36 [1.32, 1.4] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
| PPM000206 | PGS000086 (CC_Testis) |
PSS000125| European Ancestry| 170,680 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Testicular cancer | OR: 2.29 [2.13, 2.47] | — | — | Genotyping array, age, 10 PCs. | — |
| PPM002051 | PGS000086 (CC_Testis) |
PSS001024| European Ancestry| 179,537 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident testicular cancer | HR: 2.18 [1.66, 2.87] | AUROC: 0.783 C-index: 0.749 (0.034) |
— | Age at assessment, genotyping array, PCs(1-15) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM000491 | PGS000160 (cGRS_Prostate) |
PSS000280| European Ancestry| 6,828 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Prostate cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.73 [1.38, 2.17] | — | — |
| PPM000480 | PGS000160 (cGRS_Prostate) |
PSS000280| European Ancestry| 6,828 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Prostate cancer | — | — | Mean realative risk: 1.3 [1.21, 1.38] Wilcoxon test (case vs. control) p-value: 2.07e-18 |
— | — |
| PPM000900 | PGS000333 (PRS_PC) |
PSS000447| European Ancestry| 48,851 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident prostate cancer | — | C-index: 0.866 | — | age, family history, history of benign prostate hyperplasia, genotyping array/batch, 10 ancestry PCs | 10-year risk |
| PPM000895 | PGS000333 (PRS_PC) |
PSS000447| European Ancestry| 48,851 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident prostate cancer | — | C-index: 0.857 | — | age, genotyping array/batch, 10 ancestry PCs | 10-year risk |
| PPM000890 | PGS000333 (PRS_PC) |
PSS000446| European Ancestry| 59,126 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Prostate cancer (incident and prevalent cases) | HR: 1.83 [1.78, 1.9] | — | — | genotyping array/batch, 10 ancestry PCs | — |
| PPM014914 | PGS000333 (PRS_PC) |
PSS009926| Multi-ancestry (including European)| 91,106 individuals |
PGP000356 | Varma A et al. Cancer Med (2022) |Ext. |
Reported Trait: Prostate cancer | — | AUROC: 0.788 [0.758, 0.819] | — | Age, father's history, body mass index (BMI), smoking status, glycated hemoglobin, C-reactive protein, insulin-like growth factor 1, number of sex partners, diabetes diagnosis, and diabetes medication | — |
| PPM000987 | PGS000348 (PRS_PrCa) |
PSS000502| European Ancestry| 1,039 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer in men with a family history of prostate cancer | OR: 1.9 [1.53, 2.4] | — | — | Age | — |
| PPM000986 | PGS000348 (PRS_PrCa) |
PSS000501| European Ancestry| 3,891 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer | — | AUROC: 0.64 | — | Age | — |
| PPM000985 | PGS000348 (PRS_PrCa) |
PSS000501| European Ancestry| 3,891 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer | OR: 1.72 [1.59, 1.88] | AUROC: 0.64 [0.62, 0.66] | — | — | — |
| PPM000988 | PGS000348 (PRS_PrCa) |
PSS000503| European Ancestry| 2,305 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer in men with no family history of prostate cancer | OR: 1.65 [1.49, 1.84] | — | — | Age | — |
| PPM001250 | PGS000565 (PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.434 [1.336, 1.54] β: 0.361 (0.0363) |
AUROC: 0.596 [0.579, 0.615] | Nagelkerke's Pseudo-R²: 0.0271 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 2.39 [1.41, 4.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608 |
| PPM001251 | PGS000566 (PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.393 [1.3, 1.493] β: 0.332 (0.0352) |
AUROC: 0.591 [0.573, 0.609] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.152 Odds Ratio (OR, top 1% vs. Rest): 2.85 [1.76, 4.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608 |
| PPM001252 | PGS000567 (PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.505 [1.404, 1.613] β: 0.409 (0.0354) |
AUROC: 0.608 [0.59, 0.628] | Nagelkerke's Pseudo-R²: 0.0379 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 3.17 [1.98, 5.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608 |
| PPM001253 | PGS000568 (PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.426 [1.332, 1.527] β: 0.355 (0.035) |
AUROC: 0.595 [0.577, 0.614] | Nagelkerke's Pseudo-R²: 0.0281 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 1.53 [0.88, 2.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608 |
| PPM001254 | PGS000569 (PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.643 [1.531, 1.763] β: 0.496 (0.036) |
AUROC: 0.63 [0.613, 0.648] | Nagelkerke's Pseudo-R²: 0.0543 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 2.86 [1.79, 4.57] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608 |
| PPM001255 | PGS000570 (PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.572 [1.465, 1.687] β: 0.452 (0.0359) |
AUROC: 0.622 [0.604, 0.639] | Nagelkerke's Pseudo-R²: 0.0453 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 2.66 [1.63, 4.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608 |
| PPM001256 | PGS000571 (PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.67 [1.555, 1.793] β: 0.513 (0.0363) |
AUROC: 0.634 [0.617, 0.653] | Nagelkerke's Pseudo-R²: 0.0583 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 2.96 [1.85, 4.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608 |
| PPM001257 | PGS000572 (PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.537 [1.433, 1.649] β: 0.43 (0.0358) |
AUROC: 0.616 [0.597, 0.636] | Nagelkerke's Pseudo-R²: 0.0418 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.59, 6.28] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608 |
| PPM001258 | PGS000573 (PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.603 [1.495, 1.718] β: 0.472 (0.0355) |
AUROC: 0.622 [0.603, 0.641] | Nagelkerke's Pseudo-R²: 0.0497 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 2.93 [1.83, 4.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608 |
| PPM001259 | PGS000574 (PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.506 [1.406, 1.614] β: 0.41 (0.0352) |
AUROC: 0.612 [0.593, 0.63] | Nagelkerke's Pseudo-R²: 0.039 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.24, 3.52] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608 |
| PPM001260 | PGS000575 (PRSWEB_PHECODE185_C61_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.577 [1.47, 1.692] β: 0.456 (0.0359) |
AUROC: 0.619 [0.601, 0.637] | Nagelkerke's Pseudo-R²: 0.0456 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 3.1 [1.96, 4.92] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PT_MGI_20200608 |
| PPM001261 | PGS000576 (PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.489 [1.39, 1.596] β: 0.398 (0.0353) |
AUROC: 0.607 [0.589, 0.627] | Nagelkerke's Pseudo-R²: 0.0358 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 2.46 [1.5, 4.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608 |
| PPM001262 | PGS000577 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.756 [1.634, 1.886] β: 0.563 (0.0366) |
AUROC: 0.646 [0.627, 0.665] | Nagelkerke's Pseudo-R²: 0.0678 Brier score: 0.147 Odds Ratio (OR, top 1% vs. Rest): 3.57 [2.29, 5.57] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608 |
| PPM001263 | PGS000578 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.746 [1.681, 1.813] β: 0.557 (0.0192) |
AUROC: 0.653 [0.642, 0.662] | Nagelkerke's Pseudo-R²: 0.0565 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 4.31 [3.48, 5.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608 |
| PPM001264 | PGS000579 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.747 [1.626, 1.876] β: 0.558 (0.0364) |
AUROC: 0.646 [0.627, 0.664] | Nagelkerke's Pseudo-R²: 0.0675 Brier score: 0.147 Odds Ratio (OR, top 1% vs. Rest): 3.53 [2.26, 5.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608 |
| PPM001265 | PGS000580 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.748 [1.684, 1.815] β: 0.559 (0.0192) |
AUROC: 0.653 [0.643, 0.663] | Nagelkerke's Pseudo-R²: 0.0568 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 4.34 [3.51, 5.37] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608 |
| PPM001266 | PGS000581 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.79 [1.665, 1.925] β: 0.582 (0.0371) |
AUROC: 0.651 [0.634, 0.669] | Nagelkerke's Pseudo-R²: 0.071 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 4.44 [2.87, 6.87] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608 |
| PPM001267 | PGS000582 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.957 [1.882, 2.035] β: 0.671 (0.0201) |
AUROC: 0.681 [0.671, 0.692] | Nagelkerke's Pseudo-R²: 0.0776 Brier score: 0.0803 Odds Ratio (OR, top 1% vs. Rest): 4.85 [3.95, 5.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608 |
| PPM001268 | PGS000583 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.929 [1.79, 2.078] β: 0.657 (0.038) |
AUROC: 0.668 [0.651, 0.687] | Nagelkerke's Pseudo-R²: 0.0874 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 3.61 [2.28, 5.72] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608 |
| PPM001269 | PGS000584 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 2.173 [2.087, 2.263] β: 0.776 (0.0206) |
AUROC: 0.705 [0.695, 0.715] | Nagelkerke's Pseudo-R²: 0.1 Brier score: 0.0791 Odds Ratio (OR, top 1% vs. Rest): 5.58 [4.58, 6.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608 |
| PPM001270 | PGS000585 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.907 [1.771, 2.053] β: 0.645 (0.0378) |
AUROC: 0.67 [0.652, 0.688] | Nagelkerke's Pseudo-R²: 0.0837 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 3.3 [2.06, 5.29] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608 |
| PPM001271 | PGS000586 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 2.018 [1.94, 2.1] β: 0.702 (0.0203) |
AUROC: 0.687 [0.678, 0.698] | Nagelkerke's Pseudo-R²: 0.0837 Brier score: 0.0799 Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.84, 7.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608 |
| PPM001272 | PGS000587 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.906 [1.771, 2.051] β: 0.645 (0.0375) |
AUROC: 0.665 [0.647, 0.684] | Nagelkerke's Pseudo-R²: 0.0861 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 4.92 [3.21, 7.55] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608 |
| PPM001273 | PGS000588 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608) |
PSS000573| European Ancestry| 32,664 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 2.127 [2.043, 2.215] β: 0.755 (0.0206) |
AUROC: 0.699 [0.69, 0.71] | Nagelkerke's Pseudo-R²: 0.0943 Brier score: 0.0794 Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.85, 7.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608 |
| PPM001274 | PGS000589 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.63 [1.52, 1.748] β: 0.489 (0.0356) |
AUROC: 0.63 [0.612, 0.648] | Nagelkerke's Pseudo-R²: 0.0532 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 3.14 [1.99, 4.96] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608 |
| PPM001275 | PGS000590 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.516 [1.415, 1.624] β: 0.416 (0.0353) |
AUROC: 0.614 [0.595, 0.633] | Nagelkerke's Pseudo-R²: 0.0395 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.32 [1.42, 3.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608 |
| PPM001276 | PGS000591 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.608 [1.498, 1.725] β: 0.475 (0.0359) |
AUROC: 0.627 [0.608, 0.645] | Nagelkerke's Pseudo-R²: 0.051 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 3.18 [2.01, 5.02] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608 |
| PPM001277 | PGS000592 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608) |
PSS000552| European Ancestry| 5,607 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of prostate | OR: 1.537 [1.433, 1.648] β: 0.43 (0.0357) |
AUROC: 0.616 [0.598, 0.635] | Nagelkerke's Pseudo-R²: 0.0408 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.55 [1.55, 4.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608 |
| PPM001278 | PGS000593 (PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608) |
PSS000554| European Ancestry| 1,490 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of other male genital organs | OR: 1.193 [1.002, 1.419] β: 0.176 (0.0887) |
AUROC: 0.551 [0.5, 0.6] | Nagelkerke's Pseudo-R²: 0.00553 Brier score: 0.0831 Odds Ratio (OR, top 1% vs. Rest): 1.01 [0.177, 5.76] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608 |
| PPM001279 | PGS000594 (PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608) |
PSS000554| European Ancestry| 1,490 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Cancer of other male genital organs | OR: 1.227 [1.029, 1.464] β: 0.205 (0.0899) |
AUROC: 0.558 [0.506, 0.606] | Nagelkerke's Pseudo-R²: 0.00729 Brier score: 0.083 Odds Ratio (OR, top 1% vs. Rest): 1.04 [0.183, 5.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608 |
| PPM001280 | PGS000595 (PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.713 [1.33, 2.206] β: 0.538 (0.129) |
AUROC: 0.658 [0.594, 0.719] | Nagelkerke's Pseudo-R²: 0.0543 Brier score: 0.0838 Odds Ratio (OR, top 1% vs. Rest): 2.64 [0.535, 13.0] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608 |
| PPM001281 | PGS000596 (PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.68 [1.28, 2.206] β: 0.519 (0.139) |
AUROC: 0.649 [0.586, 0.714] | Nagelkerke's Pseudo-R²: 0.0475 Brier score: 0.0841 Odds Ratio (OR, top 1% vs. Rest): 3.49 [0.816, 14.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608 |
| PPM001282 | PGS000597 (PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.667 [1.296, 2.143] β: 0.511 (0.128) |
AUROC: 0.656 [0.593, 0.717] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.084 Odds Ratio (OR, top 1% vs. Rest): 2.72 [0.568, 13.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608 |
| PPM001283 | PGS000598 (PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.639 [1.263, 2.126] β: 0.494 (0.133) |
AUROC: 0.648 [0.581, 0.712] | Nagelkerke's Pseudo-R²: 0.0447 Brier score: 0.0841 Odds Ratio (OR, top 1% vs. Rest): 3.85 [0.942, 15.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608 |
| PPM001284 | PGS000599 (PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.628 [1.281, 2.069] β: 0.487 (0.122) |
AUROC: 0.637 [0.568, 0.703] | Nagelkerke's Pseudo-R²: 0.0473 Brier score: 0.0844 Odds Ratio (OR, top 1% vs. Rest): 4.35 [1.08, 17.5] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608 |
| PPM001285 | PGS000600 (PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.619 [1.267, 2.067] β: 0.482 (0.125) |
AUROC: 0.636 [0.565, 0.698] | Nagelkerke's Pseudo-R²: 0.046 Brier score: 0.0839 Odds Ratio (OR, top 1% vs. Rest): 6.35 [1.81, 22.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608 |
| PPM001286 | PGS000601 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.438 [1.132, 1.827] β: 0.363 (0.122) |
AUROC: 0.598 [0.526, 0.672] | Nagelkerke's Pseudo-R²: 0.0258 Brier score: 0.085 |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608 |
| PPM001287 | PGS000602 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608) |
PSS000574| European Ancestry| 1,484 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 2.055 [1.692, 2.496] β: 0.72 (0.0993) |
AUROC: 0.698 [0.656, 0.74] | Nagelkerke's Pseudo-R²: 0.0839 Brier score: 0.0795 Odds Ratio (OR, top 1% vs. Rest): 4.6 [1.75, 12.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608 |
| PPM001288 | PGS000603 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608) |
PSS000553| European Ancestry| 755 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 1.625 [1.27, 2.079] β: 0.485 (0.126) |
AUROC: 0.625 [0.557, 0.693] | Nagelkerke's Pseudo-R²: 0.044 Brier score: 0.084 Odds Ratio (OR, top 1% vs. Rest): 6.05 [1.73, 21.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608 |
| PPM001289 | PGS000604 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608) |
PSS000574| European Ancestry| 1,484 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Malignant neoplasm of testis | OR: 2.106 [1.729, 2.565] β: 0.745 (0.101) |
AUROC: 0.703 [0.659, 0.745] | Brier score: 0.0793 Nagelkerke's Pseudo-R²: 0.0882 Odds Ratio (OR, top 1% vs. Rest): 4.6 [1.75, 12.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608 |
| PPM001365 | PGS000662 (GRS.PCa.269) |
PSS000596| European Ancestry| 199,969 individuals |
PGP000122 | Conti DV et al. Nat Genet (2021) |
Reported Trait: Prostate Cancer | — | AUROC: 0.833 | Odds ratio (OR, top 10% versus 40-60% GRS): 4.17 Overall Net Reclassification Index (NRI [%]): 59.4 |
Age, 10 PCs | — |
| PPM001366 | PGS000662 (GRS.PCa.269) |
PSS000595| African Ancestry| 2,633 individuals |
PGP000122 | Conti DV et al. Nat Genet (2021) |
Reported Trait: Prostate Cancer | — | AUROC: 0.679 | Odds ratio (OR, top 10% versus 40-60% GRS): 3.53 | Age, 10 PCs, study | — |
| PPM001951 | PGS000662 (GRS.PCa.269) |
PSS000976| European Ancestry| 12,472 individuals |
PGP000168 | Plym A et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prevalent prostate cancer | OR: 2.04 | — | Odds ratio (OR, top 10% vs. middle 20%): 3.89 [3.24, 4.68] | Age at blood collection, genotyping platform, PCs(1-10) | Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome. |
| PPM001952 | PGS000662 (GRS.PCa.269) |
PSS000976| European Ancestry| 12,472 individuals |
PGP000168 | Plym A et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prevalent prostate cancer | — | — | Odds ratio (OR, bottom 10% vs. middle 20%): 0.34 [0.25, 0.46] | Age at blood collection, genotyping platform, PCs(1-10) | Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome. |
| PPM001953 | PGS000662 (GRS.PCa.269) |
PSS000976| European Ancestry| 12,472 individuals |
PGP000168 | Plym A et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Elevated prostate specific antigen | OR: 1.54 | — | — | Age at blood collection, genotyping platform, PCs(1-10) | Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome. |
| PPM001954 | PGS000662 (GRS.PCa.269) |
PSS000975| African Ancestry| 524 individuals |
PGP000168 | Plym A et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prevalent prostate cancer | — | — | Odds ratio (OR, top 10% vs. middle 20%): 3.81 [1.48, 10.19] | Age at blood collection, genotyping platform, PCs(1-2) | Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome. |
| PPM001955 | PGS000662 (GRS.PCa.269) |
PSS000975| African Ancestry| 524 individuals |
PGP000168 | Plym A et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Prevalent prostate cancer | — | — | Odds ratio (OR, bottom 10% vs. middle 20%): 0.15 [0.01, 0.92] | Age at blood collection, genotyping platform, PCs(1-2) | Only 261 of the original 269 SNPs were available for analysis due to no imputation of the X chromosome. |
| PPM001970 | PGS000662 (GRS.PCa.269) |
PSS000983| European Ancestry| 81,094 individuals |
PGP000173 | Darst BF et al. Eur Urol (2021) |Ext. |
Reported Trait: Prostate cancer in carriers of rare pathogenic, likely pathogenic and/or deleterious germline variants | OR: 2.62 [2.51, 2.74] | — | — | Age, PCs (1-10) | Only 267 SNPs from PGS000662 were utilised. 2 SNPs were not included as they were not present in the UK Biobank (UKB) data and had an imputation info score of > 0.50 (median info score = 0.99). |
| PPM012964 | PGS000662 (GRS.PCa.269) |
PSS009633| Multi-ancestry (including European)| 110,706 individuals |
PGP000308 | Schaid DJ et al. Am J Hum Genet (2022) |Ext. |
Reported Trait: Prostate cancer | — | — | Relative Risk (RR): 2.14 [2.09, 2.19] | Ancestry, study | — |
| PPM012965 | PGS000662 (GRS.PCa.269) |
PSS009632| European Ancestry| 91,623 individuals |
PGP000308 | Schaid DJ et al. Am J Hum Genet (2022) |Ext. |
Reported Trait: Prostate cancer | — | — | Relative Risk (RR: 30 - 55 years old): 2.56 [2.47, 2.65] Relative Risk (RR: 55 - 60 years old): 2.39 Relative Risk (RR: 60 - 65 years old): 2.24 Relative Risk (RR: 65 - 70 years old): 2.04 Relative risk per adjusted standard error (OPERA) per year of age: 0.00014 Relative Risk (RR: 70 - 88 years old): 1.86 [1.76, 1.98] |
— | — |
| PPM014985 | PGS000662 (GRS.PCa.269) |
PSS009945| European Ancestry| 6,715 individuals |
PGP000367 | Green HD et al. Br J Cancer (2022) |Ext. |
Reported Trait: Prostate cancer incidence in men with symptoms | OR: 2.12 [1.86, 2.41] | — | — | — | — |
| PPM014986 | PGS000662 (GRS.PCa.269) |
PSS009945| European Ancestry| 6,715 individuals |
PGP000367 | Green HD et al. Br J Cancer (2022) |Ext. |
Reported Trait: Prostate cancer incidence in men with symptoms | — | AUROC: 0.772 [0.744, 0.8] | — | Age | — |
| PPM014987 | PGS000662 (GRS.PCa.269) |
PSS009945| European Ancestry| 6,715 individuals |
PGP000367 | Green HD et al. Br J Cancer (2022) |Ext. |
Reported Trait: Prostate cancer incidence in men with symptoms | — | AUROC: 0.782 [0.755, 0.81] | — | Age, family history, symptom profile | — |
| PPM015482 | PGS000662 (GRS.PCa.269) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Prostate cancer | OR: 1.86 [1.41, 2.47] | AUROC: 0.579 [0.558, 0.601] | — | — | — |
| PPM015485 | PGS000662 (GRS.PCa.269) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (tumor stage T4) | OR: 1.17 [0.95, 1.43] | AUROC: 0.505 [0.435, 0.574] | — | — | — |
| PPM015487 | PGS000662 (GRS.PCa.269) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (Gleason score >=8) | OR: 1.26 [1.15, 1.4] | AUROC: 0.523 [0.488, 0.559] | — | — | — |
| PPM015500 | PGS000662 (GRS.PCa.269) |
PSS009964| Multi-ancestry (including European)| 10,120 individuals |
PGP000377 | Plym A et al. Clin Cancer Res (2022) |Ext. |
Reported Trait: Risk of prostate cancer with family history of prostate or breast cancer | — | — | Hazard Ratio (HR, top vs. bottom quartile): 6.95 [5.57, 8.66] | Age (underlying time-scale), calendar period of DNA collection (1993-1999, 2005-2006), and genetic ancestry (principal components 1-3) | — |
| PPM015501 | PGS000662 (GRS.PCa.269) |
PSS009964| Multi-ancestry (including European)| 10,120 individuals |
PGP000377 | Plym A et al. Clin Cancer Res (2022) |Ext. |
Reported Trait: Prostate cancer death with family history of prostate or breast cancer | — | — | Hazard Ratio (HR, top vs. bottom quartile): 4.84 [2.59, 9.03] | Age (underlying time-scale), calendar period of DNA collection (1993-1999, 2005-2006), and genetic ancestry (principal components 1-3) | — |
| PPM015510 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Prostate cancer risk in 10 years | OR: 2.12 [1.55, 2.93] | — | — | — | — |
| PPM015511 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Total prostate cancer risk in 10 years | — | AUROC: 0.932 [0.918, 0.947] | — | — | — |
| PPM015512 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Gleason <=7 prostate cancer risk in 10 years | — | AUROC: 0.943 [0.928, 0.959] | — | — | — |
| PPM015513 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Gleason >=8 prostate cancer risk in 10 years | — | AUROC: 0.942 [0.919, 0.964] | — | — | — |
| PPM015514 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Localized prostate cancer risk in 10 years | — | AUROC: 0.936 [0.918, 0.953] | — | — | — |
| PPM015515 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Non-localized prostate cancer risk in 10 years | — | AUROC: 0.948 [0.922, 0.974] | — | — | — |
| PPM015516 | PGS000662 (GRS.PCa.269) |
PSS009970| Multi-ancestry (including European)| 4,448 individuals |
PGP000380 | Chou A et al. Cancer Epidemiol Biomarkers Prev (2022) |Ext. |
Reported Trait: Lethal prostate cancer risk in 10 years | — | AUROC: 0.961 [0.941, 0.982] | — | — | — |
| PPM017262 | PGS000662 (GRS.PCa.269) |
PSS010181| Multi-ancestry (including European)| 655 individuals |
PGP000452 | Schaffer KR et al. JAMA Intern Med (2023) |Ext. |
Reported Trait: Any prostate cancer on biopsy | OR: 2.0 [1.6, 2.4] | — | — | Age | — |
| PPM017263 | PGS000662 (GRS.PCa.269) |
PSS010181| Multi-ancestry (including European)| 655 individuals |
PGP000452 | Schaffer KR et al. JAMA Intern Med (2023) |Ext. |
Reported Trait: Any prostate cancer on biopsy | — | C-index: 0.71 [0.66, 0.74] | — | Prostate Biopsy Collaborative Group risk calculator (age, PSA level prior to biopsy, digital rectal exam findings, ancestry (African vs. other), prior biopsy status, family history of prostate cancer) | — |
| PPM018702 | PGS000662 (GRS.PCa.269) |
PSS011074| East Asian Ancestry| 308 individuals |
PGP000494 | Ho PJ et al. Elife (2023) |Ext. |
Reported Trait: Prostate cancer | — | AUROC: 0.72 [0.7, 0.75] | Hazard ratio (HR, high vs low tertile): 8.99 [5.27, 15.35] | age at recruitment | — |
| PPM019114 | PGS000662 (GRS.PCa.269) |
PSS011185| European Ancestry| 189,338 individuals |
PGP000508 | Dite GS et al. Prostate (2023) |Ext. |
Reported Trait: Prostate cancer | — | — | Hazard Ratio (HR per change in transformed PRS): 5.846 [4.264, 8.013] | age, family history | Effect sized based on ln(PRS) |
| PPM021705 | PGS000662 (GRS.PCa.269) |
PSS011753| European Ancestry| 3,368 individuals |
PGP000659 | Hurwitz LM et al. Environ Res (2023) |Ext. |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, PGS above median vs PGS below median): 1.17 [1.02, 1.35] | Age at enrollment, state of residence | — |
| PPM021706 | PGS000662 (GRS.PCa.269) |
PSS011754| European Ancestry| 2,794 individuals |
PGP000659 | Hurwitz LM et al. Environ Res (2023) |Ext. |
Reported Trait: Aggressive prostate cancer | — | — | Odds ratio (OR, PGS above median vs PGS below median): 1.17 [0.97, 1.41] | Age at enrollment, state of residence | — |
| PPM001624 | PGS000714 (PRS55_PC) |
PSS000840| European Ancestry| 5,138 individuals |
PGP000130 | Sipeky C et al. Sci Rep (2020) |
Reported Trait: Prostate cancer | OR: 2.13 [1.9, 2.39] | AUROC: 0.618 [0.6, 0.63] | — | — | — |
| PPM001625 | PGS000714 (PRS55_PC) |
PSS000841| European Ancestry| 4,683 individuals |
PGP000130 | Sipeky C et al. Sci Rep (2020) |
Reported Trait: Prostate cancer (clinical cases) | OR: 2.18 [1.93, 2.45] | AUROC: 0.622 [0.61, 0.64] | — | — | — |
| PPM001626 | PGS000714 (PRS55_PC) |
PSS000843| European Ancestry| 2,855 individuals |
PGP000130 | Sipeky C et al. Sci Rep (2020) |
Reported Trait: Prostate cancer (screening trial detected) | OR: 1.92 [1.56, 2.37] | AUROC: 0.597 [0.57, 0.63] | — | — | — |
| PPM001627 | PGS000714 (PRS55_PC) |
PSS000842| European Ancestry| 2,591 individuals |
PGP000130 | Sipeky C et al. Sci Rep (2020) |
Reported Trait: Metastatic prostate cancer | OR: 1.47 | AUROC: 0.549 | — | — | — |
| PPM001644 | PGS000719 (PRS_Prostate) |
PSS000860| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident prostate cancer | — | AUROC: 0.662 [0.655, 0.67] | — | Genotyping array | — |
| PPM001645 | PGS000719 (PRS_Prostate) |
PSS000860| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |
Reported Trait: Incident prostate cancer | — | AUROC: 0.669 [0.661, 0.676] | — | family history of cancer (in first-degree relatives), genotyping array | — |
| PPM001674 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 20% vs. bottom 20%): 4.42 [4.16, 4.67] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM001676 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 2% vs. middle 40%): 3.67 [3.48, 3.87] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM001678 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR bottom 20% vs. middle 40%): 0.51 [0.49, 0.52] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM001680 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (top 20% vs. bottom 20%): 4.71 [4.38, 5.05] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM001682 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (top 2% vs. middle 40%): 3.89 [3.64, 4.13] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM001684 | PGS000733 (PHS46+African) |
PSS000874| African Ancestry| 6,271 individuals |
PGP000139 | Karunamuni RA et al. Int J Cancer (2020) |
Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (bottom 20% vs. middle 40%): 0.5 [0.48, 0.52] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
| PPM015483 | PGS000733 (PHS46+African) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Prostate cancer | OR: 1.58 [1.2, 2.11] | AUROC: 0.547 [0.525, 0.569] | — | — | — |
| PPM015488 | PGS000733 (PHS46+African) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (tumor stage T4) | OR: 0.96 [0.78, 1.17] | AUROC: 0.568 [0.494, 0.631] | — | — | — |
| PPM015489 | PGS000733 (PHS46+African) |
PSS009959| African Ancestry| 2,631 individuals |
PGP000373 | Kim MS et al. Genome Biol (2022) |Ext. |
Reported Trait: Aggressive prostate cancer (Gleason score >=8) | OR: 1.18 [1.07, 1.13] | AUROC: 0.515 [0.479, 0.55] | — | — | — |
| PPM001790 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.32 [4.99, 5.7] | — | — |
| PPM001791 | PGS000741 (PCa_PHS2) |
PSS000924| Multi-ancestry (including European)| 71,856 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.54 [5.18, 5.93] | — | — |
| PPM001792 | PGS000741 (PCa_PHS2) |
PSS000923| Multi-ancestry (excluding European)| 2,382 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 4.49 [3.23, 6.33] | — | — |
| PPM001793 | PGS000741 (PCa_PHS2) |
PSS000922| Multi-ancestry (excluding European)| 6,253 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 2.54 [2.08, 3.1] | — | — |
| PPM001797 | PGS000741 (PCa_PHS2) |
PSS000922| Multi-ancestry (excluding European)| 6,253 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 2.43 [1.51, 4.05] | — | — |
| PPM001798 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer mortality (age at death) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.68 [5.07, 6.46] | — | — |
| PPM001800 | PGS000741 (PCa_PHS2) |
PSS000924| Multi-ancestry (including European)| 71,856 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer in men with a family history of prostate cancer | β: 2.06 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 4.8 | — | — |
| PPM001795 | PGS000741 (PCa_PHS2) |
PSS000924| Multi-ancestry (including European)| 71,856 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.62 [5.25, 6.05] | — | — |
| PPM001803 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer | β: 2.16 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.12 | — | — |
| PPM001804 | PGS000741 (PCa_PHS2) |
PSS000924| Multi-ancestry (including European)| 71,856 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer | β: 2.1 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 4.93 | — | — |
| PPM001805 | PGS000741 (PCa_PHS2) |
PSS000923| Multi-ancestry (excluding European)| 2,382 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer | β: 1.73 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 3.6 | — | — |
| PPM001806 | PGS000741 (PCa_PHS2) |
PSS000922| Multi-ancestry (excluding European)| 6,253 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer | β: 1.1 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 2.16 | — | — |
| PPM001807 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer mortality in men with a family history of prostate cancer | β: 2.2 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.29 | — | — |
| PPM001794 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.88 [5.48, 6.34] | — | — |
| PPM001796 | PGS000741 (PCa_PHS2) |
PSS000923| Multi-ancestry (excluding European)| 2,382 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Aggressive prostate cancer (age at diagnosis) | — | — | Hazard ratio (HR, top 20% vs. bottom 20%): 5.16 [3.45, 7.78] | — | — |
| PPM001799 | PGS000741 (PCa_PHS2) |
PSS000925| Multi-ancestry (excluding European)| 80,491 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer in men with a family history of prostate cancer | β: 1.98 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 4.48 | — | — |
| PPM001801 | PGS000741 (PCa_PHS2) |
PSS000923| Multi-ancestry (excluding European)| 2,382 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer in men with a family history of prostate cancer | β: 1.89 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 4.17 | — | — |
| PPM001802 | PGS000741 (PCa_PHS2) |
PSS000922| Multi-ancestry (excluding European)| 6,253 individuals |
PGP000149 | Huynh-Le MP et al. Nat Commun (2021) |
Reported Trait: Prostate cancer in men with a family history of prostate cancer | β: 1.11 | — | Hazard ratio (HR, top 20% vs. bottom 20%): 2.22 | — | — |
| PPM002489 | PGS000741 (PCa_PHS2) |
PSS001118| Ancestry Not Reported| 3,279 individuals |
PGP000219 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer mortality (age at death) | HR: 3.41 [2.78, 4.17] | — | — | — | — |
| PPM002490 | PGS000741 (PCa_PHS2) |
PSS001118| Ancestry Not Reported| 3,279 individuals |
PGP000219 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer (age at diagnosis) | HR: 5.35 [4.97, 5.76] | — | — | — | — |
| PPM002491 | PGS000741 (PCa_PHS2) |
PSS001118| Ancestry Not Reported| 3,279 individuals |
PGP000219 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Aggressive prostate cancer (age at diagnosis) | HR: 3.78 [3.45, 4.13] | — | — | — | — |
| PPM002492 | PGS000741 (PCa_PHS2) |
PSS001118| Ancestry Not Reported| 3,279 individuals |
PGP000219 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2021) |Ext. |
Reported Trait: Prostate cancer mortality (age at death) | HR: 2.45 [1.99, 2.97] β: 0.9 |
— | — | Family history of prostate cancer, alcohol intake, diabetes history | — |
| PPM001808 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 4.45 [3.68, 5.06] | — | — |
| PPM001809 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 7.85 [6.04, 9.33] | — | — |
| PPM001810 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Prostate cancer (age of onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.37 [0.33, 0.4] | — | — |
| PPM001814 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 5.09 [3.84, 6.05] | — | — |
| PPM001815 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 9.45 [6.17, 11.79] | — | — |
| PPM001816 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.34 [0.29, 0.39] | — | — |
| PPM001820 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 5% vs. middle 40%): 4.28 [3.49, 4.96] | — | — |
| PPM001821 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, top 20% vs. bottom 20%): 7.47 [5.49, 9.07] | — | — |
| PPM001822 | PGS000742 (PHS166) |
PSS000926| European Ancestry| 6,411 individuals |
PGP000150 | Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021) |
Reported Trait: Non-clinically significant prostate cancer (age at onset) | — | — | Hazard Ratio (HR, bottom 20% vs. middle 40%): 0.37 [0.33, 0.42] | — | — |
| PPM001907 | PGS000751 (PRS_PrCa_EuropeanWeighted) |
PSS000953| Hispanic or Latin American Ancestry| 4,324 individuals |
PGP000156 | Du Z et al. Int J Cancer (2019) |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, top 10% vs. middle 50%): 3.1 [2.55, 3.76] | Age, study, PCs(1-10) | Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF ≥ 0.001 and imputation r^2 ≥ 0.3 in Latino men. |
| PPM001908 | PGS000751 (PRS_PrCa_EuropeanWeighted) |
PSS000953| Hispanic or Latin American Ancestry| 4,324 individuals |
PGP000156 | Du Z et al. Int J Cancer (2019) |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, top 1% vs. middle 50%): 4.02 [2.46, 6.55] | Age, study, PCs(1-10) | Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF ≥ 0.001 and imputation r^2 ≥ 0.3 in Latino men. |
| PPM001909 | PGS000751 (PRS_PrCa_EuropeanWeighted) |
PSS000953| Hispanic or Latin American Ancestry| 4,324 individuals |
PGP000156 | Du Z et al. Int J Cancer (2019) |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, bottom 10% vs. middle 50%): 0.38 [0.28, 0.51] | Age, study, PCs(1-10) | Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF ≥ 0.001 and imputation r^2 ≥ 0.3 in Latino men. |
| PPM001910 | PGS000751 (PRS_PrCa_EuropeanWeighted) |
PSS000953| Hispanic or Latin American Ancestry| 4,324 individuals |
PGP000156 | Du Z et al. Int J Cancer (2019) |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, bottom 1% vs. middle 50%): 0.25 [0.09, 0.67] | Age, study, PCs(1-10) | Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF ≥ 0.001 and imputation r^2 ≥ 0.3 in Latino men. |
| PPM002066 | PGS000795 (CC_Prostate_IV) |
PSS001023| European Ancestry| 184,225 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident prostate cancer | HR: 1.77 [1.72, 1.82] | AUROC: 0.769 C-index: 0.768 (0.004) |
R²: 0.51 | Age at assessment, family history of prostate cancer, genotyping array, PCs(1-15), family history of prostate cancer | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002069 | PGS000795 (CC_Prostate_IV) |
PSS001023| European Ancestry| 184,225 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident prostate cancer | — | AUROC: 0.766 C-index: 0.763 (0.004) |
R²: 0.496 | Age, genotyping array, PCs(1-15) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002067 | PGS000796 (CC_Testis_IV) |
PSS001024| European Ancestry| 179,537 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident testicular cancer | HR: 2.26 [1.71, 2.99] | AUROC: 0.787 C-index: 0.766 (0.033) |
R²: 0.605 | Age at assessment, genotyping array, PCs(1-15) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
| PPM002516 | PGS000878 (PRS4_PC) |
PSS001135| East Asian Ancestry| 638 individuals |
PGP000224 | Oh JJ et al. Front Oncol (2020) |
Reported Trait: Prostate cancer | — | AUROC: 0.637 | Odds Ratio (OR, top 25% vs bottom 25%): 4.2 [2.32, 7.98] | Age | — |
| PPM002522 | PGS000881 (GRS72_PCa) |
PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Number of positive prostate cancer tumour cores at diagnostic biposy | OR: 1.23 [1.06, 1.41] | — | — | Age at diagnosis, study site | — |
| PPM002523 | PGS000881 (GRS72_PCa) |
PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Number of positive prostate cancer tumour cores at surveillance biposy | OR: 1.26 [1.11, 1.44] | — | — | Age at diagnosis, study site | — |
| PPM002524 | PGS000881 (GRS72_PCa) |
PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Bilateral positive prostate cancer tumor cores at diagnostic biopsy | OR: 1.27 [1.01, 1.61] | — | — | Age at diagnosis, study site | — |
| PPM002525 | PGS000881 (GRS72_PCa) |
PSS001140| European Ancestry| 1,237 individuals |
PGP000227 | Xu J et al. Prostate (2021) |
Reported Trait: Bilateral positive prostate cancer tumor cores at surveillance biopsy | OR: 1.19 [1.04, 1.36] | — | — | Age at diagnosis, study site | — |
| PPM008293 | PGS001111 (GBE_cancer1038) |
PSS007626| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Male genital tract cancer | — | AUROC: 0.94061 [0.92454, 0.95668] | R²: 0.33303 Incremental AUROC (full-covars): 0.00101 PGS R2 (no covariates): 0.00403 PGS AUROC (no covariates): 0.56122 [0.49463, 0.62782] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008294 | PGS001111 (GBE_cancer1038) |
PSS007627| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Male genital tract cancer | — | AUROC: 0.87441 [0.81711, 0.93171] | R²: 0.13571 Incremental AUROC (full-covars): 0.0 PGS R2 (no covariates): 0.0007 PGS AUROC (no covariates): 0.45176 [0.26684, 0.63669] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008295 | PGS001111 (GBE_cancer1038) |
PSS007628| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Male genital tract cancer | — | AUROC: 0.88352 [0.86817, 0.89886] | R²: 0.21048 Incremental AUROC (full-covars): 0.00892 PGS R2 (no covariates): 0.01449 PGS AUROC (no covariates): 0.61572 [0.57768, 0.65376] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008296 | PGS001111 (GBE_cancer1038) |
PSS007629| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Male genital tract cancer | — | AUROC: 0.85217 [0.80773, 0.89661] | R²: 0.15181 Incremental AUROC (full-covars): 0.00129 PGS R2 (no covariates): 0.00325 PGS AUROC (no covariates): 0.54773 [0.44057, 0.65489] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008297 | PGS001111 (GBE_cancer1038) |
PSS007630| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Male genital tract cancer | — | AUROC: 0.8538 [0.84546, 0.86213] | R²: 0.18861 Incremental AUROC (full-covars): 0.00805 PGS R2 (no covariates): 0.00804 PGS AUROC (no covariates): 0.58084 [0.56034, 0.60134] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008542 | PGS001164 (GBE_cancer1045) |
PSS007643| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Testicular cancer | — | AUROC: 0.89735 [0.86792, 0.92679] | R²: 0.1704 Incremental AUROC (full-covars): 0.01226 PGS R2 (no covariates): 0.01529 PGS AUROC (no covariates): 0.62484 [0.5376, 0.71208] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008543 | PGS001164 (GBE_cancer1045) |
PSS007644| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Testicular cancer | — | AUROC: 0.9816 [0.96678, 0.99641] | R²: 0.29699 Incremental AUROC (full-covars): 0.00299 PGS R2 (no covariates): 0.00616 PGS AUROC (no covariates): 0.386 [0.0998, 0.67219] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008544 | PGS001164 (GBE_cancer1045) |
PSS007645| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Testicular cancer | — | AUROC: 0.83915 [0.8185, 0.85981] | R²: 0.1291 Incremental AUROC (full-covars): 0.03126 PGS R2 (no covariates): 0.01573 PGS AUROC (no covariates): 0.62956 [0.58302, 0.67611] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008953 | PGS001291 (GBE_cancer1044) |
PSS007636| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.92615 [0.91516, 0.93714] | R²: 0.36445 Incremental AUROC (full-covars): 0.0009 PGS R2 (no covariates): 0.00433 PGS AUROC (no covariates): 0.55467 [0.51548, 0.59387] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008954 | PGS001291 (GBE_cancer1044) |
PSS007637| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.97011 [0.94971, 0.99051] | R²: 0.40156 Incremental AUROC (full-covars): 0.00138 PGS R2 (no covariates): 0.01286 PGS AUROC (no covariates): 0.63402 [0.52345, 0.74459] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008955 | PGS001291 (GBE_cancer1044) |
PSS007638| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.91101 [0.90322, 0.91879] | R²: 0.29589 Incremental AUROC (full-covars): 0.01454 PGS R2 (no covariates): 0.03164 PGS AUROC (no covariates): 0.65437 [0.62906, 0.67968] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008956 | PGS001291 (GBE_cancer1044) |
PSS007639| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.9026 [0.88127, 0.92393] | R²: 0.25031 Incremental AUROC (full-covars): 0.01068 PGS R2 (no covariates): 0.02013 PGS AUROC (no covariates): 0.62511 [0.56383, 0.6864] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008957 | PGS001291 (GBE_cancer1044) |
PSS007640| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.8892 [0.88431, 0.89409] | R²: 0.27234 Incremental AUROC (full-covars): 0.01941 PGS R2 (no covariates): 0.02942 PGS AUROC (no covariates): 0.63978 [0.62584, 0.65373] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009346 | PGS001805 (portability-PLR_185) |
PSS009275| European Ancestry| 8,501 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.1532 [0.1323, 0.1739] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009347 | PGS001805 (portability-PLR_185) |
PSS009049| European Ancestry| 1,468 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.168 [0.1175, 0.2176] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009348 | PGS001805 (portability-PLR_185) |
PSS008603| European Ancestry| 2,749 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0919 [0.0546, 0.129] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009349 | PGS001805 (portability-PLR_185) |
PSS008381| Greater Middle Eastern Ancestry| 664 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.1243 [0.0476, 0.1996] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009350 | PGS001805 (portability-PLR_185) |
PSS008157| South Asian Ancestry| 3,182 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0832 [0.0484, 0.1177] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009351 | PGS001805 (portability-PLR_185) |
PSS007945| East Asian Ancestry| 575 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0843 [0.0011, 0.1663] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009353 | PGS001805 (portability-PLR_185) |
PSS008829| African Ancestry| 1,711 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0537 [0.006, 0.1011] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009352 | PGS001805 (portability-PLR_185) |
PSS007727| African Ancestry| 844 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0638 [-0.0044, 0.1315] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011002 | PGS002016 (portability-ldpred2_185) |
PSS009275| European Ancestry| 8,501 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.1489 [0.128, 0.1696] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011003 | PGS002016 (portability-ldpred2_185) |
PSS009049| European Ancestry| 1,468 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.1605 [0.1099, 0.2103] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011004 | PGS002016 (portability-ldpred2_185) |
PSS008603| European Ancestry| 2,749 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0944 [0.057, 0.1314] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011006 | PGS002016 (portability-ldpred2_185) |
PSS008157| South Asian Ancestry| 3,182 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0875 [0.0528, 0.1219] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011007 | PGS002016 (portability-ldpred2_185) |
PSS007945| East Asian Ancestry| 575 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0813 [-0.0018, 0.1634] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011008 | PGS002016 (portability-ldpred2_185) |
PSS007727| African Ancestry| 844 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0792 [0.011, 0.1466] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011009 | PGS002016 (portability-ldpred2_185) |
PSS008829| African Ancestry| 1,711 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.0467 | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011005 | PGS002016 (portability-ldpred2_185) |
PSS008381| Greater Middle Eastern Ancestry| 664 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Cancer of prostate | — | — | Partial Correlation (partial-r): 0.1504 [0.0741, 0.225] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM012760 | PGS002240 (prscs_prostatecancer) |
PSS009544| European Ancestry| 687,352 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 2.14 [2.09, 2.19] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012770 | PGS002240 (prscs_prostatecancer) |
PSS009548| South Asian Ancestry| 15,256 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 2.54 [1.98, 3.26] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012765 | PGS002240 (prscs_prostatecancer) |
PSS009540| African Ancestry| 15,236 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.43 [1.21, 1.69] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012739 | PGS002241 (ldpred_prostatecancer) |
PSS009520| European Ancestry| 110,597 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.79 [1.68, 1.91] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012743 | PGS002241 (ldpred_prostatecancer) |
PSS009516| East Asian Ancestry| 178,726 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.69 [1.64, 1.74] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012747 | PGS002241 (ldpred_prostatecancer) |
PSS009528| European Ancestry| 69,422 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.8 [1.72, 1.88] | — | — | birth year, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012751 | PGS002241 (ldpred_prostatecancer) |
PSS009536| European Ancestry| 25,696 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.66 [1.57, 1.76] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012755 | PGS002241 (ldpred_prostatecancer) |
PSS009532| African Ancestry| 1,535 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.19 [0.91, 1.55] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012759 | PGS002241 (ldpred_prostatecancer) |
PSS009544| European Ancestry| 687,352 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.91 [1.86, 1.96] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012764 | PGS002241 (ldpred_prostatecancer) |
PSS009540| African Ancestry| 15,236 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.35 [1.14, 1.61] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012769 | PGS002241 (ldpred_prostatecancer) |
PSS009548| South Asian Ancestry| 15,256 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 2.21 [1.73, 2.81] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012735 | PGS002241 (ldpred_prostatecancer) |
PSS009524| European Ancestry| 258,402 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Prostate cancer | OR: 1.96 [1.91, 2.01] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
| PPM012919 | PGS002268 (PRS_csPCa) |
PSS009617| East Asian Ancestry| 1,133 individuals |
PGP000298 | Song SH et al. Investig Clin Urol (2022) |
Reported Trait: Clinically significant prostate cancer | — | AUROC: 0.7 [0.667, 0.734] | OR (very high vs moderate group): 4.92 | — | — |
| PPM017160 | PGS002268 (PRS_csPCa) |
PSS010141| East Asian Ancestry| 3,695 individuals |
PGP000442 | Song SH et al. Sci Rep (2023) |Ext. |
Reported Trait: Aggressive prostate cancer (Grade 3 or above) | — | — | Hazard Ratio (HR, top 25% vs bottom 25%): 2.026 [1.678, 2.446] | — | Only 22 SNPs from PGS002268 were utilised. 7 SNPs were not included due to inadequately low allele frequencies or call rates. rs72725879 was replaced with the next highest performing variant (rs1456315) in the same LD block (Locus PRNCR1) due to replication inconsistencies. |
| PPM017161 | PGS002268 (PRS_csPCa) |
PSS010140| East Asian Ancestry| 3,695 individuals |
PGP000442 | Song SH et al. Sci Rep (2023) |Ext. |
Reported Trait: Aggressive prostate cancer (Grade 2 or above) | — | — | Hazard Ratio (HR, top 25% vs bottom 25%): 4.649 [3.544, 6.098] | — | Only 22 SNPs from PGS002268 were utilised. 7 SNPs were not included due to inadequately low allele frequencies or call rates. rs72725879 was replaced with the next highest performing variant (rs1456315) in the same LD block (Locus PRNCR1) due to replication inconsistencies. |
| PPM017162 | PGS002268 (PRS_csPCa) |
PSS010139| East Asian Ancestry| 3,695 individuals |
PGP000442 | Song SH et al. Sci Rep (2023) |Ext. |
Reported Trait: Early-onset prostate cancer | — | AUROC: 0.627 [0.55, 0.703] | — | — | Only 22 SNPs from PGS002268 were utilised. 7 SNPs were not included due to inadequately low allele frequencies or call rates. rs72725879 was replaced with the next highest performing variant (rs1456315) in the same LD block (Locus PRNCR1) due to replication inconsistencies. |
| PPM015448 | PGS002791 (PRS126_Pca) |
PSS009957| European Ancestry| 104,586 individuals |
PGP000371 | Ruan X et al. Prostate (2022) |
Reported Trait: Prostate cancer risk | — | — | Odds Ratio (OR, top vs average percentile): 3.79 [3.46, 4.16] | disease diagnostic age or age at recruitment, subgroups and 10 principal components | — |
| PPM015449 | PGS002792 (PRS67_Pca) |
PSS009955| African Ancestry| 3,008 individuals |
PGP000371 | Ruan X et al. Prostate (2022) |
Reported Trait: Prostate cancer risk | — | — | Odds Ratio (OR, top vs average percentile): 1.77 [1.22, 2.58] | disease diagnostic age or age at recruitment, subgroups and 10 principal components | — |
| PPM015450 | PGS002793 (PRS84_Pca) |
PSS009956| East Asian Ancestry| 1,190 individuals |
PGP000371 | Ruan X et al. Prostate (2022) |
Reported Trait: Prostate cancer risk | — | — | Odds Ratio (OR, top vs average percentile): 2.87 [1.29, 6.4] | disease diagnostic age or age at recruitment, subgroups and 10 principal components | — |
| PPM015506 | PGS002796 (GRS232_Eur) |
PSS009968| European Ancestry| 888,086 individuals |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Reported Trait: Prostate cancer | OR: 1.46 [1.45, 1.46] | — | — | age, 10 genetic PCs | — |
| PPM015507 | PGS002797 (GRS67_His) |
PSS009969| Hispanic or Latin American Ancestry| 81,109 individuals |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Reported Trait: Prostate cancer | OR: 1.5 [1.46, 1.53] | — | — | age, 10 genetic PCs | — |
| PPM015508 | PGS002798 (GRS128_Afr) |
PSS009966| African Ancestry| 30,472 individuals |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Reported Trait: Prostate cancer | OR: 1.44 [1.4, 1.47] | — | — | age, 10 genetic PCs | — |
| PPM015509 | PGS002799 (GRS138_EA) |
PSS009967| East Asian Ancestry| 13,985 individuals |
PGP000379 | Shi Z et al. Eur Urol Open Sci (2022) |
Reported Trait: Prostate cancer | OR: 1.34 [1.28, 1.42] | — | — | age, 10 genetic PCs | — |
| PPM016134 | PGS003331 (PHS290) |
PSS010046| Ancestry Not Reported| 6,411 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Any prostate cancer | β: 2.11 | — | Hazard ratio (HR, top vs bottom 20%): 11.16 [10.48, 11.88] | — | — |
| PPM016135 | PGS003331 (PHS290) |
PSS010046| Ancestry Not Reported| 6,411 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Clinically significant prostate cancer | β: 2.32 | — | Hazard ratio (HR, top vs bottom 20%): 13.73 [12.43, 15.16] | — | — |
| PPM016136 | PGS003331 (PHS290) |
PSS010043| African Ancestry| 6,253 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Any prostate cancer | β: 1.64 | — | Hazard ratio (HR, top vs bottom 20%): 5.95 [5.59, 6.34] | — | — |
| PPM016137 | PGS003331 (PHS290) |
PSS010043| African Ancestry| 6,253 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Clinically significant prostate cancer | β: 1.67 | — | Hazard ratio (HR, top vs bottom 20%): 7.07 [6.58, 7.6] | — | — |
| PPM016138 | PGS003331 (PHS290) |
PSS010044| Additional Asian Ancestries| 2,378 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Any prostate cancer | β: 1.99 | — | Hazard ratio (HR, top vs bottom 20%): 8.75 [8.21, 9.32] | — | — |
| PPM016139 | PGS003331 (PHS290) |
PSS010044| Additional Asian Ancestries| 2,378 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Clinically significant prostate cancer | β: 1.89 | — | Hazard ratio (HR, top vs bottom 20%): 10.31 [9.58, 11.11] | — | — |
| PPM016140 | PGS003331 (PHS290) |
PSS010045| European Ancestry| 3,279 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Any prostate cancer | β: 2.13 | — | Hazard ratio (HR, top vs bottom 20%): 10.87 [10.21, 11.57] | — | — |
| PPM016141 | PGS003331 (PHS290) |
PSS010045| European Ancestry| 3,279 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Clinically significant prostate cancer | β: 2.13 | — | Hazard ratio (HR, top vs bottom 20%): 11.18 [10.34, 12.09] | — | — |
| PPM016142 | PGS003331 (PHS290) |
PSS010045| European Ancestry| 3,279 individuals |
PGP000397 | Huynh-Le MP et al. Prostate Cancer Prostatic Dis (2022) |
Reported Trait: Fatal prostate cancer | β: 1.68 | — | Hazard ratio (HR, top vs bottom 20%): 7.73 [6.45, 9.27] | — | — |
| PPM016145 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Fatal prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 4.42 [3.91, 5.02] | — | — |
| PPM016146 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Metastatic prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 4.89 [4.57, 5.21] | — | — |
| PPM016147 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 5.2 [5.09, 5.31] | — | — |
| PPM016149 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Metastatic prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 4.15 [3.81, 4.53] | self-reported Race and Ethnicity, Family History | — |
| PPM016150 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 4.69 [4.57, 4.81] | self-reported Race and Ethnicity, Family History | — |
| PPM016148 | PGS003331 (PHS290) |
PSS010049| Multi-ancestry (including European)| 590,750 individuals |
PGP000400 | Pagadala MS et al. J Natl Cancer Inst (2022) |Ext. |
Reported Trait: Fatal prostate cancer | — | — | Hazard ratio (HR, highest vs. lowest quintile): 4.17 [3.59, 4.88] | self-reported Race and Ethnicity, Family History | — |
| PPM016258 | PGS003383 (best_PRAD) |
PSS010084| European Ancestry| 133,752 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: prostate adenocarcinoma | — | AUROC: 0.813 | R²: 0.0798 | age, top 20 genetic principal components | — |
| PPM017067 | PGS003415 (PGS268_PCa) |
PSS010112| European Ancestry| 170,850 individuals |
PGP000428 | Nyberg T et al. J Clin Oncol (2022) |
Reported Trait: 5 years incident prostate cancer risk | — | C-index: 0.79 [0.783, 0.797] | — | — | — |
| PPM017068 | PGS003415 (PGS268_PCa) |
PSS010112| European Ancestry| 170,850 individuals |
PGP000428 | Nyberg T et al. J Clin Oncol (2022) |
Reported Trait: 10 years incident prostate cancer risk | — | C-index: 0.772 [0.768, 0.777] | — | — | — |
| PPM017071 | PGS003418 (PRState_Eur) |
PSS010114| African Ancestry| 4,533 individuals |
PGP000430 | Pagadala MS et al. BMC Cancer (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.52 [0.5, 0.53] | — | genetics, age and family history | — |
| PPM017072 | PGS003419 (PRState_Trans) |
PSS010114| African Ancestry| 4,533 individuals |
PGP000430 | Pagadala MS et al. BMC Cancer (2022) |
Reported Trait: Prostate cancer | — | AUROC: 0.66 [0.65, 0.68] | — | genetics, age and family history | — |
| PPM017264 | PGS003460 (PRS278_PCa) |
PSS010182| African Ancestry| 801 individuals |
PGP000453 | Chen F et al. Eur Urol (2023) |
Reported Trait: Prostate cancer | OR: 1.68 [1.45, 1.94] | — | — | — | — |
| PPM019149 | PGS003460 (PRS278_PCa) |
PSS011212| African Ancestry| 113 individuals |
PGP000516 | Soh P X.Y. et al. Nature Communications (2023) |Ext. |
Reported Trait: Aggresiveness of prostate cancer (ISUP = 3, 4, 5 vs ISUP = 1, 2) | OR: 1.13 [0.67, 1.9] | — | — | age | — |
| PPM019148 | PGS003460 (PRS278_PCa) |
PSS011212| African Ancestry| 113 individuals |
PGP000516 | Soh P X.Y. et al. Nature Communications (2023) |Ext. |
Reported Trait: Aggresiveness of prostate cancer (ISUP = 4, 5 or PSA >= 20 ng/ml vs the rest) | OR: 1.24 [0.65, 2.34] | — | — | age | — |
| PPM018499 | PGS003743 (PRS118_PrC) |
PSS010992| European Ancestry| 408 individuals |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Reported Trait: Prostate cancer | OR: 1.58 [1.41, 1.76] | — | — | — | — |
| PPM018571 | PGS003765 (GRS.PCa.451) |
PSS011032| African Ancestry| 556 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 2.08 | — | Odds ratio (OR, top 10% vs 40-60%): 4.93 | Age, 10 PCs | — |
| PPM018568 | PGS003765 (GRS.PCa.451) |
PSS011033| European Ancestry| 12,848 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 2.21 | — | Odds ratio (OR, top 10% vs 40-60%): 4.33 | Age, 10 PCs | — |
| PPM018569 | PGS003766 (GRS.PCa.451.TOPMed) |
PSS011035| European Ancestry| 13,781 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 2.09 | — | Odds ratio (OR, top 10% vs 40-60%): 3.95 | Age, 10 PCs | — |
| PPM018573 | PGS003766 (GRS.PCa.451.TOPMed) |
PSS011031| African Ancestry| 4,665 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 1.78 | — | Odds ratio (OR, top 10% vs 40-60%): 3.54 | Age, sub-studies, 10 PCs | — |
| PPM018570 | PGS003766 (GRS.PCa.451.TOPMed) |
PSS011030| European Ancestry| 30,898 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 2.32 | — | Odds ratio (OR, top 10% vs 40-60%): 3.51 | Age, 10 PCs | — |
| PPM018572 | PGS003766 (GRS.PCa.451.TOPMed) |
PSS011034| African Ancestry| 639 individuals |
PGP000488 | Wang A W et al. Nature Genetics (2023) |
Reported Trait: Prostate Cancer | OR: 1.76 | — | Odds ratio (OR, top 10% vs 40-60%): 3.54 | Age, 10 PCs | — |
| PPM019527 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.76053 β: 0.56562 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019528 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.01802 β: 0.70212 |
AUROC: 0.69 | — | 0 | beta = log(or)/sd_pgs |
| PPM019529 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.88516 β: 0.63401 |
AUROC: 0.68 | — | 0 | beta = log(or)/sd_pgs |
| PPM019530 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.83859 β: 0.609 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019531 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.1788 β: 0.77878 |
AUROC: 0.72 | — | 0 | beta = log(or)/sd_pgs |
| PPM019532 | PGS003985 (dbslmm.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.93585 β: 0.66054 |
AUROC: 0.68 | — | 0 | beta = log(or)/sd_pgs |
| PPM019575 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.81364 β: 0.59533 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019576 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.03616 β: 0.71106 |
AUROC: 0.69 | — | 0 | beta = log(or)/sd_pgs |
| PPM019577 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.06139 β: 0.72338 |
AUROC: 0.7 | — | 0 | beta = log(or)/sd_pgs |
| PPM019578 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.87698 β: 0.62967 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019579 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.36011 β: 0.85871 |
AUROC: 0.73 | — | 0 | beta = log(or)/sd_pgs |
| PPM019580 | PGS004001 (lassosum.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.94974 β: 0.6677 |
AUROC: 0.68 | — | 0 | beta = log(or)/sd_pgs |
| PPM019545 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.82561 β: 0.60191 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019546 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.07696 β: 0.73091 |
AUROC: 0.7 | — | 0 | beta = log(or)/sd_pgs |
| PPM019547 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.12005 β: 0.75144 |
AUROC: 0.71 | — | 0 | beta = log(or)/sd_pgs |
| PPM019548 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.93632 β: 0.66079 |
AUROC: 0.68 | — | 0 | beta = log(or)/sd_pgs |
| PPM019549 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.34953 β: 0.85421 |
AUROC: 0.72 | — | 0 | beta = log(or)/sd_pgs |
| PPM019550 | PGS004027 (ldpred2.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.03998 β: 0.71294 |
AUROC: 0.69 | — | 0 | beta = log(or)/sd_pgs |
| PPM019509 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.84253 β: 0.61114 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019510 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.11238 β: 0.74782 |
AUROC: 0.7 | — | 0 | beta = log(or)/sd_pgs |
| PPM019511 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.18207 β: 0.78027 |
AUROC: 0.72 | — | 0 | beta = log(or)/sd_pgs |
| PPM019512 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.93239 β: 0.65876 |
AUROC: 0.68 | — | 0 | beta = log(or)/sd_pgs |
| PPM019513 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.29829 β: 0.83216 |
AUROC: 0.73 | — | 0 | beta = log(or)/sd_pgs |
| PPM019514 | PGS004042 (ldpred2.CV.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.05028 β: 0.71798 |
AUROC: 0.69 | — | 0 | beta = log(or)/sd_pgs |
| PPM019557 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.85139 β: 0.61594 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019558 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.08323 β: 0.73392 |
AUROC: 0.7 | — | 0 | beta = log(or)/sd_pgs |
| PPM019559 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.14725 β: 0.76419 |
AUROC: 0.71 | — | 0 | beta = log(or)/sd_pgs |
| PPM019560 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.88479 β: 0.63382 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019561 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.22812 β: 0.80116 |
AUROC: 0.72 | — | 0 | beta = log(or)/sd_pgs |
| PPM019562 | PGS004055 (megaprs.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.98362 β: 0.68492 |
AUROC: 0.68 | — | 0 | beta = log(or)/sd_pgs |
| PPM019551 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.85969 β: 0.62041 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019552 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.07288 β: 0.72894 |
AUROC: 0.7 | — | 0 | beta = log(or)/sd_pgs |
| PPM019553 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.03055 β: 0.70831 |
AUROC: 0.7 | — | 0 | beta = log(or)/sd_pgs |
| PPM019554 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.89962 β: 0.64165 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019555 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.24918 β: 0.81056 |
AUROC: 0.71 | — | 0 | beta = log(or)/sd_pgs |
| PPM019556 | PGS004071 (megaprs.CV.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.99361 β: 0.68995 |
AUROC: 0.69 | — | 0 | beta = log(or)/sd_pgs |
| PPM019569 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.80595 β: 0.59109 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019570 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.05454 β: 0.72005 |
AUROC: 0.69 | — | 0 | beta = log(or)/sd_pgs |
| PPM019571 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.12708 β: 0.75475 |
AUROC: 0.71 | — | 0 | beta = log(or)/sd_pgs |
| PPM019572 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.87036 β: 0.62613 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019573 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.10264 β: 0.74319 |
AUROC: 0.7 | — | 0 | beta = log(or)/sd_pgs |
| PPM019574 | PGS004085 (prscs.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.9751 β: 0.68062 |
AUROC: 0.68 | — | 0 | beta = log(or)/sd_pgs |
| PPM019563 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.79229 β: 0.58349 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019564 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.0553 β: 0.72042 |
AUROC: 0.69 | — | 0 | beta = log(or)/sd_pgs |
| PPM019566 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.88631 β: 0.63462 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019567 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.13119 β: 0.75668 |
AUROC: 0.71 | — | 0 | beta = log(or)/sd_pgs |
| PPM019568 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.97586 β: 0.681 |
AUROC: 0.68 | — | 0 | beta = log(or)/sd_pgs |
| PPM019565 | PGS004099 (prscs.CV.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.15033 β: 0.76562 |
AUROC: 0.72 | — | 0 | beta = log(or)/sd_pgs |
| PPM019515 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.59583 β: 0.46739 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019516 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.7257 β: 0.54563 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019517 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.56915 β: 0.45054 |
AUROC: 0.63 | — | 0 | beta = log(or)/sd_pgs |
| PPM019518 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.64521 β: 0.49787 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019519 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.93373 β: 0.65945 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019520 | PGS004109 (pt_clump.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.75123 β: 0.56032 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019521 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.65268 β: 0.5024 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019522 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.82864 β: 0.60357 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019523 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.6915 β: 0.52562 |
AUROC: 0.64 | — | 0 | beta = log(or)/sd_pgs |
| PPM019524 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.73299 β: 0.54985 |
AUROC: 0.65 | — | 0 | beta = log(or)/sd_pgs |
| PPM019526 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.81235 β: 0.59462 |
AUROC: 0.66 | — | 0 | beta = log(or)/sd_pgs |
| PPM019525 | PGS004125 (pt_clump_nested.CV.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.09235 β: 0.73829 |
AUROC: 0.69 | — | 0 | beta = log(or)/sd_pgs |
| PPM019539 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.83755 β: 0.60843 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019540 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.10912 β: 0.74627 |
AUROC: 0.7 | — | 0 | beta = log(or)/sd_pgs |
| PPM019541 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.09532 β: 0.73971 |
AUROC: 0.71 | — | 0 | beta = log(or)/sd_pgs |
| PPM019542 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.94637 β: 0.66597 |
AUROC: 0.68 | — | 0 | beta = log(or)/sd_pgs |
| PPM019543 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.33868 β: 0.84959 |
AUROC: 0.73 | — | 0 | beta = log(or)/sd_pgs |
| PPM019544 | PGS004139 (sbayesr.auto.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.05644 β: 0.72098 |
AUROC: 0.69 | — | 0 | beta = log(or)/sd_pgs |
| PPM019533 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011221| European Ancestry| 68,516 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.88737 β: 0.63519 |
AUROC: 0.67 | — | 0 | beta = log(or)/sd_pgs |
| PPM019534 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011232| European Ancestry| 171,474 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.16613 β: 0.77294 |
AUROC: 0.7 | — | 0 | beta = log(or)/sd_pgs |
| PPM019535 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011245| South Asian Ancestry| 19,738 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.17738 β: 0.77812 |
AUROC: 0.71 | — | 0 | beta = log(or)/sd_pgs |
| PPM019536 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011261| European Ancestry| 31,410 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 1.96184 β: 0.67388 |
AUROC: 0.68 | — | 0 | beta = log(or)/sd_pgs |
| PPM019537 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011289| South Asian Ancestry| 4,976 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.33409 β: 0.84762 |
AUROC: 0.73 | — | 0 | beta = log(or)/sd_pgs |
| PPM019538 | PGS004155 (UKBB_EnsPGS.GCST006085.Prostate_cancer) |
PSS011274| European Ancestry| 41,305 individuals |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Reported Trait: Prostate cancer | OR: 2.07191 β: 0.72847 |
AUROC: 0.69 | — | 0 | beta = log(or)/sd_pgs |
| PPM020315 | PGS004251 (PRS125_prostate) |
PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Prostate cancer | HR: 1.78 [1.72, 1.85] | — | — | first 10 genetic principal components | — |
| PPM020696 | PGS004581 (PRCA_PRSCS) |
PSS011367| European Ancestry| 151,620 individuals |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Reported Trait: Prostate cancer | OR: 2.13 [2.08, 2.17] | — | — | — | — |
| PPM020753 | PGS004599 (PRS102_Pca) |
PSS011391| East Asian Ancestry| 3,166 individuals |
PGP000577 | Ruan X et al. J Clin Med (2023) |
Reported Trait: Prostate cancer | — | — | Odds ratio (OR, high vs low PRS quintile): 3.63 [2.61, 5.0] | Age, family history, PSA, %fPSA, 10 PCs | — |
| PPM020754 | PGS004599 (PRS102_Pca) |
PSS011391| East Asian Ancestry| 3,166 individuals |
PGP000577 | Ruan X et al. J Clin Med (2023) |
Reported Trait: Prostate cancer | — | AUROC: 0.904 [0.887, 0.921] | — | Age, familiy history, log(prostate volume), log(prostate health index) | — |
| PPM020757 | PGS004601 (PRS17_Pca) |
PSS011394| East Asian Ancestry| 2,628 individuals |
PGP000579 | Wu Y et al. Clin Genet (2023) |
Reported Trait: Prostate cancer in males undergoing prostate biopsy | — | — | p (PRS in cases vs controls): 5.56e-17 | — | — |
| PPM020758 | PGS004601 (PRS17_Pca) |
PSS011393| East Asian Ancestry| 2,425 individuals |
PGP000579 | Wu Y et al. Clin Genet (2023) |
Reported Trait: Primary prostate cancer | — | — | p (PRS in cases vs controls): 3.31e-23 | — | — |
| PPM020879 | PGS004694 (prostate_cancer) |
PSS011438| European Ancestry| 18,514 individuals |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Reported Trait: Prostate cancer | — | AUROC: 0.6894 | — | — | — |
| PPM021040 | PGS004815 (prostate_cancer_PRSmix_eur) |
PSS011469| European Ancestry| 3,782 individuals |
PGP000604 | Truong B et al. Cell Genom (2024) |
Reported Trait: Prostate cancer | — | — | Incremental R2 (Full model versus model with only covariates): 0.112 [0.093, 0.131] | age, sex, PC1, PC2, PC3, PC4, PC5, PC6, PC7, PC8, PC9, PC10 | Incremental R2 (Full model versus model with only covariates) |
| PPM021041 | PGS004816 (prostate_cancer_PRSmixPlus_eur) |
PSS011469| European Ancestry| 3,782 individuals |
PGP000604 | Truong B et al. Cell Genom (2024) |
Reported Trait: Prostate cancer | — | — | Incremental R2 (Full model versus model with only covariates): 0.112 [0.093, 0.131] | age, sex, PC1, PC2, PC3, PC4, PC5, PC6, PC7, PC8, PC9, PC10 | Incremental R2 (Full model versus model with only covariates) |
| PPM021157 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011627| European Ancestry| 204,761 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.96 [1.92, 1.99] | — | — | PCs 1-10 | — |
| PPM021158 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011626| European Ancestry| 17,270 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.66 [1.59, 1.73] | C-index: 0.65 [0.64, 0.66] | — | PCs 1-10 | — |
| PPM021159 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011625| European Ancestry| 32,747 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.85 [1.77, 1.93] | C-index: 0.67 [0.65, 0.68] | — | PCs 1-10 | — |
| PPM021160 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011624| European Ancestry| 12,058 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.86 [1.74, 2.0] | C-index: 0.68 [0.66, 0.7] | — | PCs 1-10 | — |
| PPM021161 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011622| European Ancestry| 19,798 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 2.12 [1.69, 2.66] | — | — | PCs 1-10 | — |
| PPM021163 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011621| European Ancestry| 181,814 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.98 [1.94, 2.01] | C-index: 0.69 [0.69, 0.7] | — | PCs 1-10 | — |
| PPM021164 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011620| European Ancestry| 68,883 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.79 [1.72, 1.87] | C-index: 0.67 [0.65, 0.68] | — | PCs 1-10 | — |
| PPM021162 | PGS004872 (INTERVENE_MegaPRS_Prostate_cancer) |
PSS011623| European Ancestry| 7,018 individuals |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Reported Trait: Incident Prostate Cancer | HR: 1.61 [1.42, 1.83] | C-index: 0.66 [0.62, 0.7] | — | PCs 1-10 | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS010992 | — | — | 408 individuals | Mean = 61.67 years | European | — | TCGA | — |
| PSS000123 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 28010 | — | [ ,
100.0 % Male samples |
— | European | — | GERA, UKB | — |
| PSS010182 | — | — | [ ,
100.0 % Male samples |
— | African unspecified | — | MADCaP | — |
| PSS000125 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 28020 | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS001135 | Cases are individuals with prostate cancer. 80% of the cases are diagnosed with prostate cancer with a gleason score of ≥ 7. | — | [ ,
100.0 % Male samples |
— | East Asian (Korean) |
— | NR | — |
| PSS001140 | All individuals were prostate cancer cases undergoing active surveillance. Patients with favourable-risk prostate cancer and low-volume favourable intermediate-risk prostate cancer were enrolled. Favorable‐risk PCa was defined as Gleason grade group (GG) = 1 and prostate‐specific antigen (PSA) < 10 ng/ml. Low‐volume favorable intermediate‐risk in our study was defined as ≤2 positive cores, and only one of the following characteristics: GG ≤ 2 and/or PSA 10–20 ng/ml. At diagnostic biopsy 765 individuals had 1 tumour core, 272 had 2 tumour cores and 152 had ≥3 tumour cores. Of the individuals with 1, 2 or ≥3 positive cores at diagnostic biopsy, 1127 were unilateral and 95 were bilateral. At any surveillance biopsy 408 individuals had 1 tumour core, 297 had 2 tumour cores and 506 had ≥3 tumour cores. Of the individuals with 1, 2 or ≥3 positive cores at any surveillance biopsy, 635 were unilateral and 582 were bilateral. | — | 1,237 individuals, 100.0 % Male samples |
Mean = 65.16 years | European | — | JHH, NSUHS | — |
| PSS011627 | — | — | [
|
— | European | — | UKB | — |
| PSS008157 | — | — | 3,182 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS011212 | — | — | [ ,
100.0 % Male samples |
Median = 66.9 years Range = [45.0, 99.0] years |
Sub-Saharan African | > 98.4% African Ancestry | NR | — |
| PSS011438 | — | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS009594 | — | — | [ ,
100.0 % Male samples |
— | Not reported | — | TCGA | — |
| PSS011221 | — | — | [ ,
100.0 % Male samples |
— | European | — | EB | — |
| PSS011074 | — | — | 308 individuals, 100.0 % Male samples |
Median = 59.0 years IQR = [54.0, 64.0] years |
East Asian (Chinese) |
— | SCHS | — |
| PSS011232 | C3_PROSTATE, ICD10: C61, ICD9: 185 | — | [ ,
100.0 % Male samples |
— | European | — | FinnGen | — |
| PSS010043 | — | — | [ ,
100.0 % Male samples |
— | African unspecified | — | NR | — |
| PSS010044 | — | — | [ ,
100.0 % Male samples |
— | Asian unspecified | — | NR | — |
| PSS010045 | — | — | [ ,
100.0 % Male samples |
— | European (Swedish) |
— | COSM | — |
| PSS010046 | — | — | [ ,
100.0 % Male samples |
— | Not reported | — | ProtecT | — |
| PSS011245 | — | — | [ ,
100.0 % Male samples |
— | South Asian | — | G&H | — |
| PSS009617 | — | — | [ ,
100.0 % Male samples |
— | East Asian (Korean) |
— | NR | — |
| PSS007727 | — | — | 844 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS010049 | — | — | [ ,
100.0 % Male samples |
Median = 67.0 years | Asian unspecified | — | MVP | — |
| PSS010049 | — | — | [ ,
100.0 % Male samples |
Median = 63.0 years | African American or Afro-Caribbean (Black) |
— | MVP | — |
| PSS010049 | — | — | [ ,
100.0 % Male samples |
Median = 66.0 years | European (Hispanic White) |
— | MVP | — |
| PSS010049 | — | — | [ ,
100.0 % Male samples |
Median = 65.0 years | Native American | — | MVP | — |
| PSS010049 | — | — | [ ,
100.0 % Male samples |
Median = 68.0 years | European (Non-Hispanic White) |
— | MVP | — |
| PSS010049 | — | — | [ ,
100.0 % Male samples |
Median = 64.0 years | Other | — | MVP | — |
| PSS010049 | — | — | [ ,
100.0 % Male samples |
Median = 65.0 years | Oceanian (Pacific Islander) |
— | MVP | — |
| PSS010049 | — | — | [ ,
100.0 % Male samples |
Median = 67.0 years | Not reported | — | MVP | — |
| PSS011261 | — | — | [ ,
100.0 % Male samples |
— | European | — | HUNT | — |
| PSS009275 | — | — | 8,501 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS000446 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
| PSS000447 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [
|
— | European (Finnish) |
— | FinnGen | — |
| PSS011274 | — | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS000041 | For each cohort core data on disease status, age at diagnosis (age at observation or questionnaire for controls), family history of PrCa, and clinical factors for cases (for example, PSA at diagnosis and Gleason score) was extracted | — | [ ,
100.0 % Male samples |
— | European | — | 42 cohorts
|
These samples (OncoArray) were also used in the GWAS meta-analysis |
| PSS011289 | — | — | [ ,
100.0 % Male samples |
— | South Asian | — | UKB | — |
| PSS011469 | — | — | 3,782 individuals | — | European | — | AllofUs | — |
| PSS009632 | — | — | [ ,
100.0 % Male samples |
— | European | — | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS009633 | — | — | [ ,
100.0 % Male samples |
— | African American or Afro-Caribbean | — | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS009633 | — | — | [ ,
100.0 % Male samples |
— | Asian unspecified | — | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS009926 | The ICD-10 code used to define PCa was C61-malignant neoplasm of prostate, and the self-reported cancer code was 1044—prostate cancer. | — | [ ,
100.0 % Male samples |
— | European | White | UKB | — |
| PSS009926 | The ICD-10 code used to define PCa was C61-malignant neoplasm of prostate, and the self-reported cancer code was 1044—prostate cancer. | — | [ ,
100.0 % Male samples |
— | African unspecified | Black | UKB | — |
| PSS009926 | The ICD-10 code used to define PCa was C61-malignant neoplasm of prostate, and the self-reported cancer code was 1044—prostate cancer. | — | [ ,
100.0 % Male samples |
— | Asian unspecified | — | UKB | — |
| PSS009926 | The ICD-10 code used to define PCa was C61-malignant neoplasm of prostate, and the self-reported cancer code was 1044—prostate cancer. | — | [ ,
100.0 % Male samples |
— | Not reported | — | UKB | — |
| PSS009633 | — | — | [ ,
100.0 % Male samples |
— | European | — | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS009633 | — | — | [ ,
100.0 % Male samples |
— | Sub-Saharan African (Ghanaian) |
— | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS009633 | — | — | [ ,
100.0 % Male samples |
— | Hispanic or Latin American | — | BPC3, CGEMS, Ghana, PEGASUS | GENEVA, ICPCG, ONCO |
| PSS000840 | Cases: clinically diagnosed or screen-detected prostate cancer. Controls: free of cancer | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC, PHD | — |
| PSS000841 | Cases: clinically diagnosed with prostate cancer. Controls: free of cancer. | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC, PHD | — |
| PSS000843 | Cases: screen-detected prostate cancer. Controls: free of cancer. | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC | — |
| PSS000842 | — | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC, PHD | — |
| PSS000220 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | European, East Asian, African American or Afro-Caribbean, Oceanian, Hispanic or Latin American, South Asian, African unspecified, NR | Combined analysis of multiple ancestries, including: European, East Asian, African American, Hawaiian, Hispanic American, South Asian, Black African, Black Caribbean, and Other (not specified) | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
| PSS000221 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | African unspecified | Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
| PSS000222 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | Asian unspecified | Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
| PSS000223 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | European | Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
| PSS000224 | Age at death due to prostate cancer. | — | [ ,
100.0 % Male samples |
Mean = 70.0 years IQR = [63.0, 76.0] years |
European, East Asian, African American or Afro-Caribbean, Oceanian, Hispanic or Latin American, South Asian, African unspecified, NR | Combined analysis of multiple ancestries, including: European, East Asian, African American, Hawaiian, Hispanic American, South Asian, Black African, Black Caribbean, and Other (not specified) | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
| PSS011753 | — | — | [ ,
100.0 % Male samples |
— | European | — | AHS | — |
| PSS011754 | — | — | [ ,
100.0 % Male samples |
— | European | — | AHS | — |
| PSS008829 | — | — | 1,711 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS009648 | — | — | [ ,
100.0 % Male samples |
— | European | — | MDC | — |
| PSS009649 | — | — | [ ,
100.0 % Male samples |
— | European | — | VIP | — |
| PSS009650 | — | — | [ ,
100.0 % Male samples |
— | European | — | NR | — |
| PSS000860 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Prostate=(ICD-9 = 185 or ICD-10 = C61) | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
| PSS010084 | C61 | — | [
|
— | European (British) |
— | UKB | Controls were samples without any cancer diagnosis or self-reported cancer |
| PSS009945 | Patients in the symptomatic cohort that were diagnosed with prostate cancer within 2 years of the index date were treated as cases. Patients with no record of a prostate cancer diagnosis within 2 years of the index date were considered controls | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 69.0] years | European | — | ProtecT | — |
| PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 69.0] years | European | — | SEARCH | — |
| PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 60.0] years | European | — | UKGPCS | — |
| PSS000069 | Prostate cancer was classified as localised disease with tumour-node-metastasis (TNM) stage T1-2 N0 M0; and advanced disease (regional-distant) with stage T3 and above or any T N1 M1; as non-aggressive tumour, Gleason score <7, and aggressive tumour, Gleason score ⩾7. | Median = 13.0 years | [ ,
100.0 % Male samples |
Range = [55.0, 71.0] years | European (Finnish) |
— | ERSPC | — |
| PSS000874 | Clinically significant cancer were any of: Gleason score ≥ 7, stage T3-T4, PSA concentration ≥ 10 ng/mL, pelvic lymph nodal metastasis or distant metastasis. | — | [ ,
100.0 % Male samples |
— | African unspecified | — | 18 cohorts
|
PRACTICAL consortium |
| PSS008381 | — | — | 664 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS001023 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS001024 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS000552 | PheCode:185; ICD9CM:185, 233.4, V10.46; ICD10CM:C61, D07.5 | — | [
|
— | European | — | MGI | — |
| PSS000553 | PheCode:187.2; ICD9CM:186.0, 186.9, V10.47; ICD10CM:C62, C62.0, C62.00, C62.01, C62.02, C62.1, C62.10, C62.11, C62.12, C62.9, C62.90, C62.91, C62.92 | — | [
|
— | European | — | MGI | — |
| PSS000076 | — | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
| PSS000077 | — | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
| PSS000554 | PheCode:187; ICD9CM:186.0, 186.9, 187.1, 187.2, 187.3, 187.4, 187.5, 187.6, 187.7, 187.8, 187.9, 233.5, 233.6, 236.4, 236.5, 236.6, V10.45, V10.47, V10.48, V10.49; ICD10CM:C60, C60.0, C60.1, C60.2, C60.8, C60.9, C62, C62.0, C62.00, C62.01, C62.02, C62.1, C62.10, C62.11, C62.12, C62.9, C62.90, C62.91, C62.92, C63, C63.0, C63.00, C63.01, C63.02, C63.1, C63.10, C63.11, C63.12, C63.2, C63.7, C63.8, C63.9, D07.4, D07.6, D07.60, D07.61, D07.69, D40, D40.0, D40.1, D40.10, D40.11, D40.12, D40.8, D40.9 | — | [
|
— | European | — | MGI | — |
| PSS000075 | Breast and prostate cancer cases were defined on the basis of age at diagnosis, whichever occurred first. If breast and prostate cancer occurred at the same time, individuals were treated as patients with breast cancer. | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
| PSS000501 | Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing. NSGI controls had a minimum of 1 year clincal history available in the EHR and were exlucded if any ICD9/10 diagnosis of cancer was present at any time in the EHR. Men who tested positive for RPVs in any prostate cancer susceptibility gene were exlcuded from further analysis. | — | [ ,
100.0 % Male samples |
— | European | — | AG, JHH, NSGHI | — |
| PSS000502 | Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing. | — | [ ,
100.0 % Male samples |
— | European | — | AG, JHH | — |
| PSS000503 | Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing. | — | [ ,
100.0 % Male samples |
— | European | — | AG, JHH | — |
| PSS011329 | — | — | 115,207 individuals, 100.0 % Male samples |
— | European (British) |
— | UKB | — |
| PSS000573 | PheCode:185; ICD9:185, 233.4; ICD10:C61, D07.5 | — | [
|
— | European | — | UKB | — |
| PSS000574 | PheCode:187.2; ICD9:186, 186.0, 186.9; ICD10:C62.0, C62.1, C62.9 | — | [
|
— | European | — | UKB | — |
| PSS009957 | — | — | 104,586 individuals | — | European | — | UKB | — |
| PSS009955 | — | — | 3,008 individuals | — | African American or Afro-Caribbean (African American) |
— | AAPC | — |
| PSS009959 | — | — | [
|
— | African unspecified | — | MADCaP | — |
| PSS009956 | — | — | 1,190 individuals | — | East Asian (Chinese) |
— | NR | ChinaPCa |
| PSS010112 | — | — | 170,850 individuals, 100.0 % Male samples |
— | European | — | UKB | — |
| PSS010114 | — | — | 4,533 individuals, 100.0 % Male samples |
— | African unspecified | — | ELLIPSE | — |
| PSS009964 | — | — | 10,120 individuals, 100.0 % Male samples |
Median = 65.3 years | European, Not reported | 99% European | HPFS | — |
| PSS009966 | — | 30,472 individuals, 100.0 % Male samples |
Median = 61.0 years | African unspecified | — | NR | — | |
| PSS009967 | — | 13,985 individuals, 100.0 % Male samples |
Median = 61.0 years | East Asian | — | NR | — | |
| PSS009968 | — | 888,086 individuals, 100.0 % Male samples |
Median = 65.0 years | European | — | NR | — | |
| PSS009969 | — | 81,109 individuals, 100.0 % Male samples |
Median = 61.0 years | Hispanic or Latin American | — | NR | — | |
| PSS009970 | — | — | [ ,
100.0 % Male samples |
— | European | — | MEC | — |
| PSS009970 | — | — | [ ,
100.0 % Male samples |
— | African American or Afro-Caribbean (African American) |
— | MEC | — |
| PSS009970 | — | — | [ ,
100.0 % Male samples |
— | Native American (Native Hawaiian) |
— | MEC | — |
| PSS009970 | — | — | [ ,
100.0 % Male samples |
— | East Asian (Japanese) |
— | MEC | — |
| PSS009970 | — | — | [ ,
100.0 % Male samples |
— | Hispanic or Latin American (Latino) |
— | MEC | — |
| PSS009971 | — | — | 30,716 individuals | — | European | — | MGBB | — |
| PSS009971 | — | — | 1,807 individuals | — | African unspecified (Black) |
— | MGBB | — |
| PSS009971 | — | — | 786 individuals | — | Asian unspecified | — | MGBB | — |
| PSS009971 | — | — | 3,113 individuals | — | Other | — | MGBB | — |
| PSS011185 | — | — | [ ,
100.0 % Male samples |
Mean = 62.1 years Sd = 5.5 years |
European | — | UKB | — |
| PSS007945 | — | — | 575 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS000595 | — | — | [ ,
100.0 % Male samples |
— | African unspecified | — | CAUG | — |
| PSS000596 | — | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS000924 | Cases numbers refer to 'any prostate cancer'. Of those, 24279 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 3908 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 39,445 individuals had a family history of prostate cancer (≥1 first degree relative affected). | — | [ ,
100.0 % Male samples |
Mean = 66.0 years IQR = [60.0, 71.0] years |
European, NR | — | 60 cohorts
|
— |
| PSS000925 | Cases numbers refer to 'any prostate cancer'. Of those, 24279 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 3908 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. | — | [ ,
100.0 % Male samples |
Mean = 66.0 years IQR = [60.0, 71.0] years |
European, NR | — | 60 cohorts
|
— |
| PSS000925 | Cases numbers refer to 'any prostate cancer'. Of those, 716 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 57 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. | — | [ ,
100.0 % Male samples |
Mean = 68.0 years IQR = [62.0, 74.0] years |
Asian unspecified, NR | — | 60 cohorts
|
— |
| PSS000925 | Cases numbers refer to 'any prostate cancer'. Of those, 1424 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 18 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. | — | [ ,
100.0 % Male samples |
Mean = 62.0 years IQR = [56.0, 68.0] years |
African unspecified, NR | — | 60 cohorts
|
— |
| PSS000923 | Cases numbers refer to 'any prostate cancer'. Of those, 716 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 57 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 1028 individuals had a family history of prostate cancer (≥1 first degree relative affected). | — | [ ,
100.0 % Male samples |
Mean = 68.0 years IQR = [62.0, 74.0] years |
Asian unspecified, NR | — | 60 cohorts
|
— |
| PSS000922 | Cases numbers refer to 'any prostate cancer'. Of those, 1424 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 18 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 5557 individuals had a family history of prostate cancer (≥1 first degree relative affected). | — | [ ,
100.0 % Male samples |
Mean = 62.0 years IQR = [56.0, 68.0] years |
African unspecified, NR | — | 60 cohorts
|
— |
| PSS010140 | — | — | [ ,
100.0 % Male samples |
Mean = 67.3 years | East Asian (Korean) |
— | NR | — |
| PSS000926 | Cases included individuals with any type of prostate cancer (PCa). For any clinically significant PCa, cases were defined as individuals with any of the following: Gleason score ≥ 7, stage T3-T4, PSA concentration ≥ 10 ng/mL, pelvic lymph nodal metastasis, or distant metastasis. | — | [ ,
100.0 % Male samples |
— | European | — | ProtecT, UKGPCS | — |
| PSS010141 | — | — | [ ,
100.0 % Male samples |
Mean = 67.3 years | East Asian (Korean) |
— | NR | — |
| PSS010139 | — | — | [ ,
100.0 % Male samples |
Mean = 67.3 years | East Asian (Korean) |
— | NR | — |
| PSS010151 | — | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS011367 | — | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
| PSS000105 | Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. | — | 4,828 individuals, 100.0 % Male samples |
Mean = 59.0 years IQR = [55.0, 63.0] years |
European | — | ProtecT | — |
| PSS000105 | Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of aggressive prostate cancer (defined as any of Gleason score ≥7, stage T3-T4, PSA concentration ≥10 ng/mL, nodal metastasis, or distant metastasis) | — | [ ,
100.0 % Male samples |
Mean = 64.3 years IQR = [60.2, 67.5] years |
European | — | ProtecT | — |
| PSS000106 | Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. | — | 4,828 individuals, 100.0 % Male samples |
Mean = 59.0 years IQR = [55.0, 63.0] years |
European | — | ProtecT | — |
| PSS000106 | Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of prostate cancer. | — | [ ,
100.0 % Male samples |
Mean = 63.4 years IQR = [59.0, 67.5] years |
European | — | ProtecT | — |
| PSS000107 | Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. | — | 4,828 individuals, 100.0 % Male samples |
Mean = 59.0 years IQR = [55.0, 63.0] years |
European | — | ProtecT | — |
| PSS000107 | Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of very aggressive prostate cancer (defined as any of Gleason score ≥8, stage T3-4, positive nodes, or distant metastases) | — | [ ,
100.0 % Male samples |
— | European | — | ProtecT | — |
| PSS003583 | All individuals were BRCA1 carriers. BRCA1 pathogenic variants were categorized according to their known or predicted effect on protein function: “class I” included loss-of-function variants expected to yield unstable or no protein; “class II” included variants likely to produce stable mutant proteins. Pathology data were obtained from pathology reviews, medical, pathology or tumor registry records, or immunohistochemical staining of tissue microarrays. All cases were individuals with prostate cancer. | — | [ ,
100.0 % Male samples |
— | European | — | 31 cohorts
|
Additional cases and controls were obtained from UCHICAGO |
| PSS003584 | All individuals were BRCA2 carriers. BRCA2 pathogenic variants were categorized according to their known or predicted effect on protein function: “class I” included loss-of-function variants expected to yield unstable or no protein; “class II” included variants likely to produce stable mutant proteins. Pathology data were obtained from pathology reviews, medical, pathology or tumor registry records, or immunohistochemical staining of tissue microarrays. All cases were individuals with prostate cancer. | — | [ ,
100.0 % Male samples |
— | European | — | 36 cohorts
|
Additional cases and controls were obtained from UCHICAGO |
| PSS011620 | — | — | [
|
— | European | — | EB | — |
| PSS011621 | — | — | [
|
— | European | — | FinnGen | — |
| PSS011622 | — | — | [
|
— | European | — | G&H | — |
| PSS011623 | — | — | [
|
— | European | — | GS:SFHS | — |
| PSS011624 | — | — | [
|
— | European | — | GEL | — |
| PSS011625 | — | — | [
|
— | European | — | HUNT | — |
| PSS011626 | — | — | [
|
— | European | — | MGBB | — |
| PSS007626 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007627 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007628 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007629 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007630 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS009520 | — | — | [ ,
100.0 % Male samples |
— | European (Estonian) |
— | EB | — |
| PSS009516 | — | — | [ ,
100.0 % Male samples |
— | East Asian (Japanese) |
— | BBJ | — |
| PSS000953 | In set 1 (1034 cases), prostate cancer cases were identified by linking with the cancer registries in Hawaii and California. In set 2 (1192 cases) cases were indiviuals with prostate cancer determined by cancer diagnosis, enrollment in prostate cancer studies at University of Texas M.D. Ancerson Cancer Centre or by biposy confirmation. | — | [ ,
100.0 % Male samples |
— | Hispanic or Latin American | — | LAAPC, MDA, MEC, SABOR | — |
| PSS009049 | — | — | 1,468 individuals | — | European | Poland (NE Europe) | UKB | — |
| PSS009524 | — | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
| PSS010181 | — | — | 575 individuals, 100.0 % Male samples |
— | European | — | BioVU | — |
| PSS010181 | — | — | 80 individuals, 100.0 % Male samples |
— | African unspecified | — | BioVU | — |
| PSS007636 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS007637 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS007638 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007639 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007640 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS007643 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS007644 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS007645 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS009528 | — | — | [ ,
100.0 % Male samples |
— | European | Norwegian | HUNT | — |
| PSS009536 | — | — | [ ,
100.0 % Male samples |
— | European | — | MGBB | — |
| PSS009532 | — | — | [ ,
100.0 % Male samples |
— | African American or Afro-Caribbean | — | MGBB | — |
| PSS011391 | — | — | [ ,
100.0 % Male samples |
Median = 68.0 years IQR = [62.0, 74.0] years |
East Asian (Chinese) |
— | NR | — |
| PSS009540 | — | — | [ ,
100.0 % Male samples |
— | African unspecified | — | UKB | — |
| PSS009540 | — | — | [ ,
100.0 % Male samples |
— | African unspecified | — | UKB | — |
| PSS011394 | — | — | [ ,
100.0 % Male samples |
— | East Asian (Chinese) |
— | NR | — |
| PSS011393 | — | — | [ ,
100.0 % Male samples |
— | East Asian (Chinese) |
— | NR | — |
| PSS009544 | — | — | [ ,
100.0 % Male samples |
— | European | British | UKB | — |
| PSS009544 | — | — | [ ,
100.0 % Male samples |
— | European | British | UKB | — |
| PSS009548 | — | — | [ ,
100.0 % Male samples |
— | South Asian | — | UKB | — |
| PSS009548 | — | — | [ ,
100.0 % Male samples |
— | South Asian | — | UKB | — |
| PSS000975 | Cases were defined as having a biopsy-confirmed prostate cancer documented by a pathology report or at least two prostate cancer-related billing codes any time before or within 6 months of the date of blood collection. | — | [ ,
100.0 % Male samples |
— | African unspecified | — | MGBB | Formerly known as Partners healthcare Biobank (PHB) |
| PSS000976 | Cases were defined as having a biopsy-confirmed prostate cancer documented by a pathology report or at least two prostate cancer-related billing codes any time before or within 6 months of the date of blood collection. | — | [ ,
100.0 % Male samples |
— | European | — | MGBB | Formerly known as Partners healthcare Biobank (PHB) |
| PSS008603 | — | — | 2,749 individuals | — | European | Italy (South Europe) | UKB | — |
| PSS000280 | Primary tumor samples from TCGA | — | [ ,
100.0 % Male samples |
Mean = 62.0 years Sd = 7.0 years |
European | — | TCGA | — |
| PSS000280 | — | — | [ ,
100.0 % Male samples |
— | European | — | eMERGE | — |
| PSS000983 | Cases were individuals with malignant prostate cancer. All individuals (cases and controls) were carriers of rare pathogenic, likely pathogenic and/or deleterious germline variants in ATM, BRCA2, CHEK2, and HOXB13 genes. | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
| PSS011030 | — | — | [ ,
100.0 % Male samples |
— | European | — | EB | — |
| PSS011031 | — | — | [ ,
100.0 % Male samples |
— | African unspecified | — | MADCaP | — |
| PSS011032 | — | — | [ ,
100.0 % Male samples |
— | African American or Afro-Caribbean | — | MGBB | — |
| PSS011033 | — | — | [ ,
100.0 % Male samples |
— | European | — | MGBB | — |
| PSS001118 | Cases are individuals with prostate cancer. Of the 2163 cases, 1403 are aggressive prostate cancer cases defined as disease typically requiring treatment: Gleason score ≥7, clinical stage T3-T4, PSA concentration ≥10 ng/mL, or nodal/distant metastasis. 278 prostate cancer cases were fatal. | — | [ ,
100.0 % Male samples |
Median = 78.0 years IQR = [72.3, 84.1] years |
Not reported | — | COSM | Sample overlap exists between this dataset and the dataset used to develop/train Karunamuni et al's PGS (PGS000741) |
| PSS011035 | — | — | [ ,
100.0 % Male samples |
— | European | — | MGI | — |
| PSS011034 | — | — | [ ,
100.0 % Male samples |
— | African American or Afro-Caribbean | — | MGI | — |